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resumo
 
A hipertensão arterial pulmonar (HAP) é uma doença grave, caracterizada 
pela proliferação excessiva de células endoteliais e musculares lisas das 
artérias pulmonares, com aumento da resistência vascular pulmonar e 
sobrecarga do ventrículo direito, sendo este o principal determinante de 
prognóstico associado à patologia. O exercício físico confere vários 
benefícios ao nível da função cardiovascular, tanto em condições fisiológicas 
como patológicas, pelo que se questionou a sua potencial utilização como 
medida terapêutica na HAP. Assim, neste trabalho, numa primeira parte, 
reuniu-se o conhecimento atual sobre a adaptação do ventrículo direito face 
às alterações impostas pela HAP (Capítulo II), discutindo-se os mecanismos 
modelados pelo exercício físico. De um modo geral, o exercício físico 
aparenta prevenir a remodelação da matriz extracelular (diminuição da 
fibrose e modulação das MMPs/TIMPs), estimular a angiogénese, reduzir a 
inflamação (diminuição da infiltração celular e dos níveis de TNF-α e IL-6) e 
o stress oxidativo. Na segunda parte deste trabalho (Capítulo III), estudou-se 
os efeitos cardioprotetores do exercício físico na HAP, utilizando o modelo 
animal de monocrotalina submetido a duas semanas de exercício físico (5 
dias/semana, 60 min/dia, 25 m/min). Os resultados evidenciaram que o 
exercício físico retarda a progressão da doença, atendendo a que os ratos 
treinados apresentaram melhoria da função diastólica (pressão diastólica 
final inferior e Tau), apesar da presença de sobrecarga cardíaca (aumento da 
pressão sistólica, pressão diastólica final e elastância arterial). 
Concomitantemente, observou-se um aumento da captação de glucose para 
os cardiomiócitos do ventrículo direito através do GLUT4 seguido da sua 
oxidação a lactato, não se observando alteração da oxidação de ácidos 
gordos. Este efeito do exercício está associado a um aumento da expressão 
de proteína PGC1α e PPARγ. De um modo geral, o presente trabalho suporta 
a recomendação de exercício físico para o tratamento da HAP.  
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abstract
 
Pulmonary arterial hypertension (PAH) is a deadly disease characterized by 
progressive remodelling of the pulmonary arteries, causing a rise in 
pulmonary vascular resistance and overloading the right ventricle (RV). The 
RV response to the overload is the main prognostic determinant. Since 
exercise training provides several cardiovascular benefits in both 
physiological and pathological conditions, its use as a therapeutic tool for 
PAH has been hypothesised. In this work, we first performed a narrative 
review summarizing the current evidence about the mechanisms underlying 
the cardioprotective effects of exercise training in PAH (Chapter II). Our 
review suggests that exercise training prevents the remodelling of ECM 
(decrease fibrosis and modulation of MMPs/TIMPs), stimulate angiogenesis, 
reduce inflammation (decreased cell infiltration and levels of TNF-α and IL-
6) and oxidative stress. Secondly, we extended the comprehension of the 
cardioprotective effects of exercise training in PAH by exploring the 
metabolic changes promoted by exercise. In order to do so, we used the 
monocrotaline animal model of PAH submitted to two weeks of treadmill 
exercise training (5 days/week, 60 min/day, 25 m/min). Our data shows that 
exercise training delays the progression of the disease, as trained rats had 
improved diastolic function (lower end-diastolic pressure and tau) despite the 
presence of cardiac overload (increased peak systolic pressure, end-diastolic 
pressure and arterial elastance). This improved hemodynamic response was 
paralleled by an increased uptake of glucose to cardiomyocytes through 
GLUT4 followed by its oxidation to lactate. Exercise did not revert the 
decrease of fatty acid oxidation related to PAH. This metabolic remodelling 
was associated to an increase of PGC1α and PPARγ protein expression. 
Overall, our work supports the recommendation of exercise training for the 
management of PAH.  
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 Pulmonary arterial hypertension (PAH) is a rare, chronic and progressive form of 
pulmonary hypertension which is characterized by elevated pulmonary arterial pressure and 
pulmonary vascular resistance in blood vessels carrying the blood from right side of heart 
through lungs.1 It occurs due to the tightening and stiffening of the small pulmonary arteries 
leading to the right ventricular dysfunction and vessel obstruction. Without effective 
therapeutic interventions, patients with PAH eventually die from right heart failure.2 
According to USA and Europe register, idiopathic subtype of PAH is the most common (50-
60% of all cases).3,4 Prevalence of PAH varies occurring to the geographical distribution, 
environmental factors, sex, age and socioeconomic factors. The reported incidence of 
pulmonary arterial hypertension in the developed world is 1.1-7.6 per million adult per year.4 
PAH generally affects predominantly females and female sex is considered a risk factor for 
PAH; however, females have better survival than males. This disease is characterized by a 
hemodynamic worsening, and the treatment aims to reduce pulmonary arterial pressure as 
well as normalize the cardiac debit.2,9  
In recent years, exercise training has been recognized as a non-pharmacological 
therapeutic tool in several chronical diseases.10 In PAH, the presence of 
physiological/hemodynamic and cellular alterations reduce the functional capacity and 
tolerance to exercise training. Thus, until 2015 the exercise was considered forbidden in 
patients with this pathology.1 However, there is still a broad path ahead in knowing for 
certain whether physical exercise is responsible for attenuating or reversing structural and 
molecular alterations present in PAH. Despite these imposed PAH limitations, there is a 
growing number of studies in humans11–14 and animal models,15–19 which indicate that the 
practice of supervised physical exercise can promote beneficial effects on patients and 
animal models with PAH. However, the types of exercises to be carried out, the intensity 
and the duration of the exercise are not yet established. The results obtained in human studies 
show an improvement in the quality of life and functional capacity, an increase in the 
capacity of resistance to physical exercise and ventilatory efficiency, a general improvement 
of the cardiac function and muscle metabolism.12,16,20–22 To add new insights on this topic, 
the present work begins with a narrative review followed by an experimental work. In the 
first, we discuss what is known so far about the role of exercise training in the modulation 
of the molecular pathways underlying right ventricle dysfunction in PAH. On the second, 
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we evaluated the therapeutic effect of exercise training in the right ventricle metabolic 
remodelling in an animal model of PAH.  
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1. Pulmonary arterial hypertension  
 Pulmonary hypertension (PH) is a pathophysiological disorder encompassing 
multiple clinical conditions.1 It is defined by an increase in mean pulmonary artery pressure 
at rest ≥ 25 mmHg, as assessed by right heart catheterisation, and can complicate the majority 
of cardiovascular and respiratory diseases.1 Pulmonary hypertension is currently classified 
into five categories (Table 1).  
Table 1 – Clinic classification of pulmonary hypertension according to the 5th World Symposium on Pulmonary 
Hypertension (2013) 
 
1. Pulmonary Arterial Hypertension (PAH) 
1.1. Idiopathic PAH 
1.2. Heritable PAH 
1.2.1. BMPR2 mutation 
1.2.2. ALK-1, endoglin, Smad9, caveolin-1, KCNK3 mutation 
1.2.3. Unknown  
1.3. Drug and toxin induced 
1.4. Associated with: 
1.4.1. Connective tissue disease 
1.4.2. Human immunodeficiency virus infection 
1.4.3. Portal hypertension 
1.4.4. Congenital heart disease 
1.4.5. Schistosomiasis 
1’ Pulmonary veno-oclusive disease and/or pulmonary capillary haemagiomatosis 
1’’ Persistent pulmonary hypertension of the new-born 
2. Pulmonary hypertension due to left heart disease 
2.1. Left ventricular systolic dysfunction 
2.2. Left ventricular diastolic dysfunction 
2.3. Valvular disease 
2.4. Congenital/acquired left heart inflow/outflow tract obstruction and congenital 
cardiomyopathies  
 3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4. Sleep-disordered breathing  
3.5. Alveolar hypoventilation disorders  
3.6. Chronic exposure to high altitude 
3.7. Development lung diseases 
 4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
 5. Pulmonary hypertension with unclear multifactorial mechanisms  
5.1. Haematologic disorders: chronic haemolytic anaemia, myeloproliferative disorders, 
splenectomy  
5.2. Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis 
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders  
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental 
pulmonary hypertension  
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This classification categorises the multiple clinical conditions culminating in PH 
according to their similar clinical presentation, pathological findings, hemodynamic 
characteristics and treatment strategy.1 This review will focus on category 1, Pulmonary 
Arterial Hypertension (PAH) (Table 1). 
 
1.1.  Definition, epidemiology, clinical presentation and diagnostic 
Pulmonary arterial hypertension is a vastly underdiagnosed condition, with an 
estimated incidence of 2.4-7.6 million cases5 per year and prevalence situated between 15-
26 million cases6 worldwide. It is defined by the presence of a pre-capillary pattern in the 
invasive hemodynamic evaluation and characterised by a resting mean pulmonary artery 
pressure (PAP) superior to 25 mmHg, pulmonary vascular resistance (PVR) higher than 3 
Wood units, and pulmonary capillary wedge pressure inferior to 15mmHg (in the absence of 
other causes of PAH).1 In the presence of a suspected PAH patient, multiple exams are 
required to confirm the diagnosis, clarify the specific aetiology within the PH group and 
evaluate the functional and haemodynamic impairment. Importantly, the diagnosis of PAH 
(particularly of idiopathic PAH) is a diagnosis of exclusion.1 Regarding the clinical 
presentation, the symptoms of PAH are non-specific and include fatigue, breathlessness, 
weakness, angina, syncope and abdominal distension. Importantly, symptoms at rest are only 
reported in advanced stages of disease. The signs of PAH include right ventricle (RV) third 
sound, tricuspid insufficiency murmur, prominent right ventricular impulse and accentuated 
pulmonic valve component.1,4 The electrocardiogram (ECG) could provide evidence of PAH 
by showing RV hypertrophy, and right atrial dilatation. RV hypertrophy on ECG are present 
in 87% and 79% of patients with idiopathic PAH. The absence of these findings does not 
exclude the presence of PAH nor does it exclude severe hemodynamic abnormalities.5 
Pulmonary function and arterial blood gases tests are also performed. Arterial blood gas 
analysis may help to exclude hypoxia as supplier to PH. Pulmonary function tests are 
essentials to establish airflow obstruction or restrictive pulmonary pathology.1 Cardiac 
catheterization should be performed in patients with unexplained pulmonary hypertension 
and remains the gold standard for PH diagnosis and quantification. The following parameters 
must be recorded during right heart catheterization: pulmonary arterial pressure (systolic, 
11 
 
diastolic and mean), right atrial pressure, pulmonary wedge pressure and RV pressure.1,6 All 
patients should perform routine biochemistry and haematology tests. A range of biomarkers 
has been described in PAH, which may be of diagnostic and prognostic significance. They 
include markers of heart failure and cardiac myocyte damage.5 Examples are atrial natriuretic 
peptide (ANP) and B-typenatriuretic peptide (BNP).7 More recently, interest has turned to 
the N-terminal fragment of BNP (NT-proBNP) as an alternative biomarker to BNP, because 
it seems to provide the same information, but has advantages in terms of stability. Endothelin 
1 (ET-1), troponin T, nitric oxide (NO), acid uric, cyclic guanosine monophosphate (cGMP), 
5-hydroxytryptamine (5-HT) and von Willebrand factor are among other biomarkers that 
might be of interest.5,7 Assessment of functional capacity is also informative to evaluate the 
disease severity. Two commonly used tests are the 6 minute walk test (6MWT) and the 
cardiopulmonary exercise testing.8  
Thus, the data of the clinical history of the patient and a careful physical examination 
are crucial to the correct diagnosis of pulmonary hypertension. Attention should be given to 
previous medical conditions, drug use and family history.     
 
1.2. Pathophysiology of pulmonary arterial hypertension 
As illustrated in Table 1, PAH may be idiopathic or secondary to various conditions, 
but regardless of the underlying aetiology, patients exhibit similar pathological changes in 
the pulmonary vasculature. A wide array of pulmonary vascular changes can occur in PAH, 
predominantly affecting the small pulmonary arteries (diameter <500 mm), which include 
enhanced pulmonary arteriole contractility, endothelial dysfunction, remodelling and 
proliferation of booth endothelial and smooth muscle cells.9,10 The physiological outcome of 
these disturbances is the partial and/or total occlusion of small pulmonary arteries, causing 
an increase in PVR and imposing a hemodynamic overload to the RV. Initially, the RV will 
adapt by developing compensatory hypertrophy but ultimately cardiac dysfunction and 
failure, and premature death will ensue.11  
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1.2.1. Vasoconstriction impairment 
Vasoconstriction of pulmonary arteries is a fundamental factor in the pathogenesis of 
PAH. When present without microthrombosis and vascular remodelling (Figure 1) it 
represents a highly reversible state in the development of the disease.12 Vasoconstriction is 
mostly mediated by an imbalance between vasoactive and vasodilating factors (i.e. an excess 
of vasoconstrictors and/or a deficiency in vasodilators). Over the past years, three major 
pathways have been identified to modulate vasoconstriction and vasodilatation: 
prostacyclins, endotelin-1 or nitric oxide pathways.13,14 
Prostacyclin and thromboxane A2 belong to the prostanoid family and are produced by 
cyclooxygenase during the metabolism of arachidonic acid. The former is an effective 
vasodilator and inhibitor of platelet activation whereas the latter has the reverse effects.14 In 
PAH patients, the expression of prostacyclin synthase in the pulmonary arteries is reduced, 
which leads to a diminished production of prostacyclin in the pulmonary endothelial cells 
(Figure 1).15,16 
Endothelin (ET-1) is a peptide mostly produced by the vascular endothelium with 
potent vasoconstrictive and proliferative actions on the vascular smooth muscle cells. ET-1 
exerts its effects through the interaction with two types of receptors: ET receptor type A 
(ETA) and ET receptor type B (ETB), which belong to the G-protein-coupled receptor 
family.17 ETA receptors are located predominately on vascular smooth muscle cells and 
mediate vasoconstriction, as well as proliferation, hypertrophy and cell migration. ETB are 
found on both endothelial and smooth muscles. ETB activation on smooth cells produces 
vasoconstriction, however ETB activation on endothelial cells leads to vasoconstriction and 
antiproliferation by increasing NO and prostacyclin production. 14 As PAH progresses, the 
cellular distribution of ET-1 receptors changes (Figure 1), with increased expression of both 
constrictive ETA and ETB on smooth cells and decreased expression of vasodilatory 
endothelial ETB. In animals and patients with PAH, it was reported that ET-1 levels were 
increased in lungs and in circulation.17–19 
NO is a lipophilic gaseous molecule that can be synthetized in mammalian tissues via 
activation of one of the three NO synthase isoforms. This enzyme catalyses the formation of 
NO from L-arginine in a two-step reaction. NO is a vasodilator that modulates several 
physiologic processes, and is also capable of inhibiting leucocyte adhesion, platelet 
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aggregation, thrombus formation and vascular proliferation.20 Some studies have shown the 
relevance of NO in pulmonary physiology, particularly, in the maintenance of low blood 
pressure, which is characteristic of the circulatory system in this organ.21,22 Reduced 
availability of this gas is a main feature described in both clinical and preclinical settings of 
PAH (Figure 1).23  
 
 
The reduction of NO may be related with decreased expression and/or activity of the 
endothelial nitric oxide synthase (eNOS) enzyme, the uncoupling of eNOS, the activation of 
iNOS or by further degradation of NO by reactive oxygen and nitrogen species (RONS).24 
Figure 1 - Pathophysiology of pulmonary arterial hypertension in heart and lungs. Vascular remodelling 
and endothelial dysfunction are markers of the pathology, leading to a progressive increase in PVR and 
ultimately to RVH with increased RV systolic and diastolic pressures. Due to progressive increase in PVR, RV 
function deteriorates, eventually leading to RV failure. Figure made using Servier Medical Art.by Servier 
(https://smart.servier.com/) and modified by the author under the Creative Commons Attribution 3.0 Unported 
License (CCBY 3.0). Abbreviations: cAMP, cyclic adenosine monophosphate; COX-2, cyclooxygensase 2; 
ECE, endothelin converting enzyme; EDP, end-diastolic pressure; ESP, end-systolic pressure; ET, endothelin; 
NO, nitric oxide; PVR: pulmonary vascular resistance; RONS, reactive oxygen and nitrogen species; RVH: 
right ventricle hypertrophy 
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1.2.2. Pulmonary vascular remodelling  
The vascular obstruction seen in PAH results from a combination of increased 
vasoconstriction, abnormal vascular remodelling and in situ thrombosis of pulmonary 
vessels.25,26 Pulmonary vascular remodelling in PAH is characterised by the thickening of all 
three layers of the blood vessel wall. This thickening is the result not only of hypertrophy 
and/or hyperplasia of the predominant cell type within each of the layers (fibroblasts, 
PASMCs and endothelial cells (EC)) but also of increased deposition of extracellular matrix 
components (collagen, elastin and fibronectin).27 Additionally, it is also characterised by 
increased cellular proliferation and resistance to apoptosis.26 These changes arise from the 
loss of antimitogenic endothelial substances, like prostacyclins and NO, and increased levels 
of mitogenic substances, such as ET-1.28 Other stimuli appear from locally activated platelets, 
which release thromboxane A2 and serotonin, promoting hypertrophy and hyperplasia of 
vascular smooth muscle cells.24 The aforementioned increased deposition of extracellular 
matrix components leads to intimal narrowing and increased resistance to blood flow.20 
The uncontrolled proliferation of ECs occurs in the irreversible plexogenic lesions, 
which are complex plexiform lesions (glomeruloid-like structures) forming channels in 
branches of the pulmonary artery, They originate from remodelled pulmonary arteries and 
constitute a hallmark of severe PAH.26 The prevailing consensus is that plexiform lesions are 
formed by a proliferating network of endothelial-lined vascular channels supported by a core 
of specialized, apoptosis-resistant myofibroblasts, smooth muscle cells, or even 
undifferentiated mesenchymal cells29, ultimately obliterating the vascular lumen.18,26  
Regarding the ECs present in these complex lesions, Masri et al. found evidence that 
idiopathic PAH pulmonary artery EC have a hyperproliferative, apoptosis-resistance 
phenotype when compared with cells from healthy lung.9 Therefore, in this pathology, the 
proliferation of ECs is enhanced, while apoptosis is repressed.30 
Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) are 
overexpressed in the plexiform lesions of patients with PAH, suggesting a role for this 
angiogenic factor in the pathogenesis of PAH.29 However, pre-clinical data have been 
inconsistent in supporting this role. For instance, while VEGF was shown to be upregulated 
in rats with chronic hypoxia-induced PH31, it was downregulated in rats with monocrotaline-
induced PH.26 Moreover, when rats with established PH were treated with VEGF, the disease 
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was mitigated. This could be the result of VEGF helping in the maintenance of endothelial 
cell function, such as in the production of antiproliferative factors.31 At the same time, while 
VEGF overexpression was capable of slowing down the development of pulmonary 
hypertension in both the monocrotaline and hypoxia-induced PH, inhibition of VEGF 
signalling by sorafenib (a small multikinase inhibitor) was also able to attenuate experimental 
PH.32 Altogether, these findings delineate an intriguing and complex role for VEGF in PAH 
pathophysiology. 
 
1.3. Current therapeutic strategies 
The knowledge of the aetiology of the disease provides the basis for the choice of a 
pharmacological approach. However, since PAH appears to have a multifactorial nature, the 
treatment has remained primarily palliative. However, even if palliative, the improvement in 
the understanding of PAH pathogenesis and underlying molecular pathways over the last 
years has allowed for a significant upgrade in the treatment of this syndrome.8 Unfortunately, 
the available therapies are only capable to slowdown the progression of the disease and 
alleviate symptoms but cannot afford a definite cure. The current therapeutic options are 
summarized in Table 2, and include supportive therapies, calcium channel blockers, 
synthetic prostacyclin and prostacyclin analogues, ET-1 receptor antagonists, type 5 
phosphodiesterase inhibitors and interventional procedures.14 Importantly, if left untreated, 
survival after diagnosis is estimated to be as low as 2.8 years33, with death occurring in most 
cases from right ventricular failure.1 It should be noted that despite the major importance of 
the RV to the patient prognosis, there are no specific therapies targeting the RV function and 
remodelling. 
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Table 2 – Current pharmacological therapies 
Drug Class 
Generic 
name 
Route; Dosage Side effects 
Comments and 
Recommendations 
References 
Synthetic prostacyclin 
and prostacyclin 
analogues 
Epoprosteno
l 
cIV; up to 30 
ng/Kg/min 
Jaw pain 
Headache 
Flushing 
Nausea 
Diarrhoea 
Catheter related 
infections 
34 
Treprostinil 
cSC or O; up to 
50-60 
ng/kg/min 
Infusion site pain 
can limit dose 
escalation when 
given SC 
35–37 
Iloprost 
Inhaled; 5 µg, 
6-12 times daily 
 38 
Beraprost 
O; 120 µg four 
times per day 
Headache 
Flushing 
Only modest 
benefit in the short 
term 
39,40 
Prostacyclin receptor 
agonist 
Selexipag 
O; up to 1600 
mg bid 
Jaw pain 
Headache 
Flushing 
Nausea 
Diarrhoea 
 41,42 
Endothelin receptor 
antagonists 
Bosentan 
O; 125 mg 
twice per day 
Anaemia 
Nasopharyngitis 
Hepatoxicity Teratogenic 
 
43,44 
Ambrisenta
n O; 10 mg daily 
Anaemia 
Nasopharyngitis 
Fluid retention 
45,46 
Macitentan 47 
Type 5 
phosphodiesterase 
inhibitors 
Sildenafil 
O; 20 mg three 
times per day 
Headache 
Flushing, 
Nasal 
congestion 
Dizziness 
Visual 
disturbance 
Must not be 
combined with 
nitrates (severe 
hypotension) 
48 
Tadalafil O; 40 mg daily 
Headache 
Flushing, 
Dizziness 
visual 
disturbance 
49 
cIV, continuous intravenous; cSC, continuous subcutaneous; O, oral 
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2. The right ventricle in pulmonary arterial hypertension 
Under physiological conditions, the amount of blood ejected by the RV is identical to 
that ejected by the left ventricle (LV). However, the structural and functional characteristics 
of the RV are quite different from those of the LV.50 Contrary to the LV, the RV has a thin 
wall, which allows it to have high diastolic compliance, thus adapting to fast fluctuations in 
volume load.51 On the other hand, RV pumping function is impaired to a much greater extent 
in comparison with that of the LV when exposed to equal amounts of pressure overload.50 
Chronic pressure overload imposed by increased PVR leads to RV hypertrophy, followed by 
maladaptation and subsequent RV failure, which is the main cause of premature death in 
PAH patients.52 In fact, RV dysfunction and failure are reportedly important predictors of 
mortality in PAH.53 However, contrasting to the well-characterized pulmonary vascular 
pathology, the RV adaptation to PAH remains poorly understood. In order to further advance 
this knowledge, we will next review the main pathophysiological features of RV remodelling, 
providing an overview of the main structural, functional, cellular and molecular 
modifications already described in PAH.  
 
2.1. Functional and structural modifications 
Increased RV afterload is the primary cause of right ventricular adaptation in PAH. 
The normal right ventricle has a thin crescent shaped wall. These features allow the RV to 
adapt rapidly to changes in volume load, but not so much to pressure load.54 The normal heart 
has a pressure–volume relationship in which the RV responds to an increase in load with an 
increase in contractility. In patients with PAH, the RV initially copes with the progressive 
increase in afterload (imposed by PVR and reduced pulmonary vascular compliance) by 
increasing contractility and by developing compensatory hypertrophy. These changes allow 
right atrial pressure to remain normal and to maintain cardiac output (CO) despite the 
elevated overload.50,51 However, RV hypertrophy is only a short-term solution, with 
chronically sustained overload leading to failure of the compensatory mechanisms 
(ventricular pulmonary arterial uncoupling) and, eventually, to a transition to cardiac 
dilatation, characterised by elevated RV filling pressure and increased end-diastolic volume. 
The limits of the compensatory adaptation are poorly understood, although there is increasing 
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evidence that a mismatch between cardiac oxygen supply and demand has an important 
role.51 When the afterload rises because of PAP elevations, RV hypertrophy sustains a normal 
RV ejection fraction (RVEF) and diminishes wall stress.53 The RV also assumes a more 
rounded shape, compressing the LV. When the RV dilates, LV fillings is altered which may 
help explain the inadequate CO response to metabolic demand.51,55 In this setting, systolic 
right coronary artery flow is reduced which can lead to RV ischemia. Therefore, it has been 
suggested that the RV coronary circulation becomes more like the one seen in the LV, with 
a greater oxygen extraction at rest and a higher dependence on an increase coronary flow to 
meet an increase in myocardial oxygen demand. The increasing pressures during the RV 
filling and decreased capacity in blood ejection may be a cause of RV ischemia and decrease 
contractility.51 However, even if this mechanism first preserves cardiac function, ultimately 
it leads to diastolic dysfunction, ischemia, dilatation of the RV and even to heart failure.52,53 
In addition, RV diastolic function is also affected in PAH, as shown by their altered filling 
pattern, prolonged relaxation times, and intrinsic diastolic stiffness.56  
Several studies have evaluated the haemodynamic function  in preclinical models of 
PAH by echocardiography.24,57–61 In monocrotaline studies, this compound resulted not only 
in increased peripheral vascular resistance,60,62 but also in increased systolic and diastolic 
blood pressure in the RV,24,57–60,63 which worsened RV contractility and relaxation. At the 
same time, monocrotaline lead to an overall impairment of diastolic function,62 decreased 
artery flow velocity, and reduce the heart rate,58,62 leading to premature development of heart 
failure.57,64 (supplementary Table 1) It was also found that the rate of acceleration/ejection 
time of pulmonary artery was lower in the animals injected with monocrotaline.24,60,65 In sum, 
the overall analysis of these results evidences PAH-induced heart failure, characterized by 
RV dysfunction.  
Structurally, the foetal/neonatal RV is a thick-walled chamber that ejects blood at a 
relatively high pressure into a high-resistance vascular bed. The wall thickness of both 
ventricles concomitantly increases, and while the RV presents with a concentric geometry, 
LV’s geometry is in a quite distinct cone-shaped form. The RV can be subdivided into 3 
segments: 1) the inlet, comprising the tricuspid valve, chordae tendineae, and papillary 
muscles; 2) the trabeculated apical myocardium; and 3) the outflow region which has a 
smooth myocardial surface.66 A superficial, circumferential layer of RV myocardial fibres 
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are in continuity with the LV fibres, accounting for the systolic motion of the RV free wall 
toward the outflow tract.54 When systolic and diastolic ventricular pressures rise, an increase 
in diastolic and systolic stretch on the RV wall is verified, which initially leads to an increase 
in muscle mass (adaptative hypertrophy) due to increased protein synthesis and an increase 
in cardiomyocyte size through the addition of new sarcomeres.52 Archer and associates were 
able to distinguish two different phenotypes, depending on the cardiac adaptation to pressure 
elevation: the adaptive phenotype, where the RV is less dilated and fibrotic, the RVEF is 
preserved and remodelling is concentric; and the maladaptive phenotype, where the RV is 
dilated and fibrotic, and the remodelling is eccentric.67 However, the RV cannot maintain 
adaptative hypertrophy in the face of sustained pressure overload, and eventually there is a 
transition to dilatation. At this point there is no further increase, and even a decrease in RV 
contractility can occur, despite a further increase in load.51 One consequence of RV dilatation 
is an increase in wall tension, which increases myocardial oxygen demand and 
simultaneously decreases right ventricular perfusion, leading to further compromised 
contractility and dilatation.68 An increase in ventricular volume may also lead to functional 
tricuspid regurgitation, imposed by annular valve dilatation and chordal traction, which in 
turn results in RV volume overload, and thus further progressive annular dilatation and RV 
remodelling.69 As a consequence of the decline in RV function, the increase in RV 
contraction time and subsequent ventricular asynchrony, and decrease in RV stroke volume, 
underfilling of the LV starts to occur.70 Therefore, the LV is also impaired due to the 
development of leftwards ventricular septal bowing, resulting from prolonged RV 
contraction time and reduction of LV volume during early diastole.55 All these markers, 
together with systolic/diastolic RV dysfunction, contribute to the marked decline in cardiac 
output seen in severe PAH. When RV function has declined, a vicious cycle of events is 
underway, which, if not interrupted, leads to right heart failure.51 
 
2.2. Inflammation 
Inflammation exerts a central role in the pathogenesis of PAH. The profile of 
circulating levels of inflammatory mediators is associated with disease severity, symptom 
burden and survival in PAH patients.71 Moreover, it has been hypothesized that circulating 
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inflammatory mediators released from the pulmonary vasculature could generate or 
contribute to the inflammatory process that adversely affect the RV remodelling and 
function.72 Furthermore, there is evidence of recruitment of immune cells from the 
circulatory system to the RV, which could also contribute to the initiation and maintenance 
of cardiac inflammation.73  
 Macrophages are present in all tissues, including the heart. Expansion of cardiac 
macrophages has been documented in models of pressure overload-induced LV remodelling 
and failure.74 In opposition, data regarding the role of macrophages in RV remodelling and 
failure are still limited. The recruitment of macrophages into the RV appears to be triggered 
by increased RV afterload induced by pulmonary artery banding (PAB) in rats.75 Increased 
recruitment of macrophages has also been reported in RV autopsy samples from PAH 
patients with RV failure.71 However, due to the lack of studies in RV failure in PAH patients, 
the role of macrophages recruitment has not been well established. In fact, based on studies 
in LV remodelling and failure, the potential mechanism through which macrophages might 
contribute to RV remodelling and dysfunction include production of RONS, regulation of 
cardiac inflammation and mediation of ECM modifications.74,76  
The inflammatory mediators involved in ventricular remodelling and dysfunction can 
be produced by infiltrating immune cells, by cells from the heart tissue, or by cells of extra-
cardiac origin.77 Interleukin-6 (IL-6) is a multi-functional cytokine with a variety of 
biological activities, which have been implicated in the remodelling and failure of the heart.78 
Notably, increased expression of IL-6 mRNA has been detected in RV of patients with 
advanced heart failure.79 Elevated plasma levels of IL-6 and increased IL-6 expression has 
been described in the RV of rats with monocrotaline-induce PAH80 and in mice subjected to 
PAB.81 
The nuclear factor-κ B (NF-κB) superfamily of transcription factors has been 
associated with the regulation of a variety of physiological processes and plays a central role 
in the regulation of the inflammatory response.71 Indeed, only a handful of studies have 
investigated the role of NF-κB in RV remodelling and dysfunction. In rats subjected to PAB, 
elevated expression of activated NF-κB was found in the RV.75 Additionally, Nogueira-
Ferreira et al. investigated the activation of the non-canonical NF-κB pathway and observed 
the upregulation of NF-κB’s subunits p100/p52 and Rel-B in the RV of rats with 
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monocrotaline-induced PAH.82 Remarkably, the NK-κB inhibitor pyrrolidine 
dithiocarbamate ameliorated PAB-induced RV inflammation and fibrosis, and improved RV 
function.74 
Nowadays, the ongoing question is whether inflammation is the cause of pulmonary 
vascular disease or whether it is the consequence of a high-pressure pulmonary 
microenvironment. In this perspective, the increasing knowledge of the immune pathways 
associated with PAH supports the usefulness of tailored immunotherapy for the management 
of this disease.83 Two clinical trials are addressing immuno-modulators and their potential 
impact on different forms of PH. Rituximab is a monoclonal antibody against the B cell 
antigen CD20, which is already used in rheumatology and oncology.84 Tociizumab is a 
humanized monoclonal IL-6 receptor antibody, which has been approved for the treatment 
of rheumatoid diseases.85 However, the exact role of these inflammatory mediators in the set 
of PAH is not yet well established. A better understanding of the role of inflammation in this 
pathology will help developing novel anti-inflammatory therapies.    
 
2.3. Remodelling of the extracellular matrix  
 Cardiac fibroblasts play an important role as sensors and amplifiers of signals from 
immune cells and cardiomyocytes by secreting cytokines, growth factors and chemokines.86 
Both IL-1 and TNF-α can increase fibroblast migration and induce fibroblast production of 
other pro-inflammatory cytokines, such as IL-6 and chemokines, such as CXCL-1, -2, -5 and 
-8.87,88 Additionally, IL-1 can activate the expression of tumour growth factor beta (TGF-β), 
which is the major profibrotic cytokine that induces differentiation of fibroblasts into 
myofibroblasts. Importantly, macrophages also play an important role in the differentiation 
of fibroblasts into myofibroblast via expression of TGF-β.89 In this way, cardiac fibroblasts 
are the main effector cells in cardiac fibrosis. The presence of fibrosis in pressure-overloaded 
RV is associated with the activation and expansion of fibroblasts, which acquire a 
myofibroblast phenotype and secrete a large amount of ECM proteins, such as collagens and 
matricellular proteins.90 Direct stimulation of resident cardiac fibroblasts through the 
activation of neurohormonal or growth factor-mediated pathways may also contribute to the 
fibrotic response.91 Histological studies have revealed increased collagen deposition in the 
RV from PAH patients, which might play a central role in the development of RV 
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dysfunction and failure in this pathology.92 In experimental models of RV pressure overload, 
fibrotic remodelling of the RV is often associated with decompensation, and is usually 
evidence of severe diastolic dysfunction.56  
 Extracellular matrix (ECM) is regulated by proteolytic enzymes, such as 
metalloproteinases (MMPs), and their endogenous inhibitors, the tissue inhibitors of MMPs 
(TIMPs).93 As aforementioned, during cardiac stress induced by PAH, the cardiac fibroblast 
undergoes a transition to activated myofibroblast, that is responsible for fibrosis and the 
secretion of MMPs and other ECM enzymes, which contribute to adverse ventricular 
remodelling.94,95 An imbalance of MMPs and TIMPs, leading to the accumulation of ECM 
in the heart has been observed in several diseases, such as PAH, lung fibrosis and myocardial 
infarction. Elevated levels of serum MMP-2, MMP-9; TIMP-1 and TIMP-4 95,96 and urinary 
MMP-2 and MMP-9 have been reported in patients with PH.97 In the rodent monocrotaline-
induced PAH model, elevated MMP-2, MMP-9 and TIMP-1 levels were observed in lung 
tissue98,99 as well as in the RV.92 Myocardial expression of specific MMPs, like gelatinase 
MMP-9 and stromelysin MMP-3, was shown to be increased in both human and experimental 
dilated cardiomyopathy.100 MMPs can be induced by several molecules/pathways, such as 
the renin-angiotensin system (RAAS), bioactive peptides, and cytokines, such as TNF-
α.101,102 In the RAAS, angiotensin II plays a central role in LV remodelling, which is 
supported by evidences of a great reduction in myocardial collagen deposition in patients 
treated with the angiotensin receptor blocker losartan.103 Whether the same response would 
be seen in PAH patients with RV hypertrophy is unknown.  
 
2.4. Cardiac vascularity  
 Myocardial perfusion is a key requisite for myocardial homeostasis. 
Pathophysiological stresses like pressure overload enhance oxygen demand. As such, the 
inability to induce enough neovascularization results in deficient oxygen supply and, 
subsequently, in atrophy and loss and/or degeneration of cardiomyocytes, which could 
represent the main cause of the myocardial dysfunction present in PAH.104,105 There is ample 
evidence that some forms of pathological cardiac hypertrophy, in particular those produced 
by pressure overload are associated with a decrease in capillary density, which is more 
notorious in the subendocardial layers of the hypertrophied ventricle.31,51,106,107  
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2.5. Cellular and molecular modifications in the cardiomyocyte  
 There are several possible contributing factors explaining RV diastolic stiffness in 
PAH. The above referred hypertrophy and fibrosis (Figure 2) are known to increase 
ventricular stiffness; however, this could also be caused by modifications in the contractile 
apparatus of cardiomyocytes.56 The contractile function of cardiomyocytes is directly 
associated with Ca2+ ion homeostasis, which is involved both in the excitability of 
cardiomyocytes and in the activation of contractile filaments, promoting cellular contraction. 
As for the expression of Ca2+ regulatory proteins in the RV, PAH is known to decrease the 
expression of ryanodine receptors (RyRs) and sarco(endo)plasmic reticulum calcium ATPase 
2a (SERCA2a).62,64 Increased afterload of the RV induces a switch in myosin heavy chain 
(MHC) isoform composition from the fast α-MHC to the slower, but energetically favourable 
β-MHC.108  
 PAH imposes an adverse remodelling to the RV (Figure 2), which includes 
hypertrophy, associated with extended interstitial fibrosis, in response to pulmonary artery 
thickening and increased afterload. Myocyte hypertrophy results from increased protein 
synthesis without cell replication. It can be stimulated by stretch, noradrenaline, ET, 
angiotensin and inflammatory cytokines, such as IL-1β, all of which are thought to be 
increased in patients with PAH.103 Angiotensin, ET-1 and catecholamines, such as 
noradrenaline, bind to specific seven-transmembrane-spanning receptors that are coupled to 
heterotrimeric Gq proteins. These Gq proteins may be coupled to phospholipase Cβ (PCβ). 
This coupling is responsible for the generation of diacylglycerol (DAG), which acts as an 
intracellular ligand for protein kinase C (PKC), and for the formation of inositol-1,4,5-
triphosphate (IP3). The accumulation of this second messenger leads to the mobilization of 
internal Ca2+ by directly binding to the IP3 receptor located in the endoplasmic reticulum. 
Moreover, the generation of IP3 and subsequent mobilization of internal Ca2+ stores has been 
shown to mediate hypertrophic signalling.109,110 The MAPK signalling cascade is initiated in 
cardiac myocytes by receptors tyrosine kinase (fibroblast growth factor receptors) and stress 
stimuli, like stretch. The activation of this pathway results in the phosphorylation and 
consequent activation of p38, c-Jun N-terminal kinases (JNKs) and ERKs.111 In addition to 
the signalling events that are initiated by ligand-receptor interactions, cardiac myocytes 
directly detect mechanical deformation or stretch through an internal sensory apparatus. This 
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apparatus involves integrins, which are heterodimeric transmembrane receptors, consisting 
of α- and β-subunits, that link the extracellular matrix to the intracellular cytoskeleton.112 
Thus, hypertrophy of the RV is an initial and adaptative response to increased overload. 
 The adult healthy heart is an organ with high energy utilization rates, which is derived 
from various oxidizable energy sources, such as fatty acids, glucose, lactate, ketones and 
amino acids. In the adult heart, fatty acid oxidation (FAO) is the predominant energy source, 
but glucose metabolism contributes to adenosine triphosphate (ATP) production, albeit in a 
lower percentage.54,113 Glucose metabolism initiates with cytosolic glycolysis, which 
ultimately converts glucose to pyruvate. Pyruvate is transferred to the mitochondria where it 
serves as subtract for pyruvate dehydrogenase (PDH). If this enzyme is activated, pyruvate 
is converted to acetyl-CoA, powering the Krebs cycle and providing reducing equivalents, 
like NADH and FADH2, to the oxidative phosphorylation (OXPHOS) system for ATP 
generation.114 In the hypertrophied and failing heart (Figure 2), as previously mentioned, the 
increased systolic wall stress in the ventricular wall will lead to an increase in the energy 
demand, whereas the increased size of the cardiomyocytes and the decreased capillary 
density is anticipated to diminish the ratio oxygen supply/demand.115 Therefore, an 
imbalance between oxygen/energy supply and demand possibly contributes to the transition 
to the decompensated, failing heart. In PAH, the RV undergoes several metabolic changes, 
including an increased reliance on glycolysis, not coupled with total glucose oxidation, which 
yields lactate.116 The lactate produced promotes acidosis, leading to a reduction of 
contractility determined by the fall of intracellular pH, which affects the organelles’ activity 
within the cardiac cell, impairing RV function.117  
 Recently, data from human RV tissue demonstrated an increase in lipid accumulation 
and decrease of FAO in PAH. As a result of lipid accumulation, lipotoxic metabolites and 
RONS accumulate and initiate apoptosis in the surrounding tissues.118 The PAH-related 
elevated levels of ET-1 (Figure 2) are responsible for the stimulation of the classical signal 
transduction of Gq protein which leads to cardiomyocyte apoptosis, facilitating the opening 
of the mitochondrial membrane transition pores is promoted by Bax activation.60Previously, 
the increased expression of caspase 3119 and Bax was observed in the RV of MCT-treated 
rats, while the expression of Bcl-2 was decreased. Li et al. reported downregulated levels of 
Bcl-2 protein, while Bax and activated caspase 3 were significantly upregulated in the RV of 
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MCT-induced rats.120,121 Moreover, the cellular stress induced by RONS can start the 
activation of mitochondrial proteins that interact with domains of the Bax and Bcl-2 proteins. 
Hence, that interaction could open the transition pores in the outer mitochondrial membrane, 
helping the relocation of cytochrome c, that is released by the mitochondria. The release of 
cytochrome c is essential to the formation of apoptosomes and activation of pro-caspase 3, a 
protein directly involved in cellular apoptosis.60,122  
Figure 2 – Cellular and molecular alterations promoted by PAH in the cardiomyocyte. Activation of 
myofibroblast leads to an increase in the levels of MMPs promoting an imbalance between MMPs and TIMPs 
which leads to an increase ECM remodelling. The increased protein synthesis stimulated by stretch, 
noradrenaline, ET, angiotensin and interleukin 1b results in hypertrophy of right ventricle. In the cardiomyocyte, 
a metabolic switch is present, with an increased reliance on glycolysis, not coupled with total glucose oxidation, 
which yields lactate. Elevated levels of ET and ROS are responsible for the development of apoptosis events. 
Figure made using Servier Medical Art.by Servier (https://smart.servier.com/) and modified by the author under 
the Creative Commons Attribution 3.0 Unported License (CCBY 3.0) Abbreviations: ECM: extracellular 
matrix; EDP, end-diastolic pressure; ESP, end-systolic pressure; ET: endothelin; MMPs: metalloproteinases; 
ROS: reactive oxygen species; TIMPs: tissue inhibitors of MMPs 
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3. The protective effect of exercise in pulmonary arterial hypertension 
Exercise training in PH was initially contraindicated due to safety concerns. However, 
an increasing number of studies have pointed out its benefits in exercise capacity, peak 
oxygen consumption and quality of life of patients with PH123,124, leading the European 
Society of Cardiology to adopt guidelines in 2016 that recommend considering supervised 
exercise training in patients with PAH that are clinically stable and exhibit an optimal 
pharmacological treatment. Nevertheless, there are some conditions to the training that are 
still very much unknown, such as the optimal duration, intensity, frequency and type of 
exercise.1 The overall positive results observed in human studies have translated into the 
improvement of global cardiac function, arterial and myocardial elasticity, muscle 
metabolism in opposition to the oxidative stress, and inflammation process and adverse 
cardiopulmonary remodelling present in PAH.62,125,126 Considering the aforementioned 
benefits of exercise training, it is important to understand the mechanisms underlying those 
changes. It has been proposed that both central (pulmonary and cardiac) and peripheral 
(skeletal muscle) adaptations could contribute to the exercise-induced positive outcomes.62 
Given that cardiac function is the main prognostic outcome in PAH patients127, we will 
review the main cardiac alterations promoted by exercise.  
 
3.1. Functional and structural modifications 
Regarding the chronic effects of exercise on the cardiac hemodynamic of preclinical 
models of PAH, different benefits, such as normalization of the pulmonary artery flow 
velocity64, maintenance of RV systolic pressure63 and attenuation of the RV systolic and 
diastolic dysfunction were observed.65 Furthermore, evidences of the reestablishment of the 
resting heart rate, reduction of changes in the myocardial acceleration during isovolumetric 
contraction and relaxation time, as well as inhibition of changes in the maximum systolic 
velocity of the tricuspid annular plane were detected.62 Additionally, when performed prior 
to PAH induction, exercise training normalized end-diastolic pressure and diastolic 
function.58 Exercise preconditioning was able to prevent RV diastolic dysfunction, which 
was the main alteration observed in the cardiac function of sedentary128 Monocrotaline 
(MCT)-treated animals. Heart rate (HR) was found to be impaired in these animals, having 
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been previously related with reduced responsiveness to sympathetic stimulation. Exercised 
MCT animals also showed decreased HR but this was probably a training effect since no 
differences were noted in comparison to its corresponding control group. Part of this 
cardioprotective effect can be attributed to the prevention of RV overload, which is supported 
by the fact that exercised MCT animals showed a reduction of RV Pmax and a significant 
reduction in the pulmonary artery remodelling.58 
Structurally, a reduction in pulmonary artery tunica media thickness is present in MCT 
trained models. This change in exercised models could contribute to an attenuation of 
pulmonary vascular resistance and may lead to a reduction in RV afterload. Exercise training 
is responsible for a decrease in interstitial volume and an increase in intramyocardial vessels’ 
volume when compared with sedentary MCT models.57,63 These adaptive structural changes 
in the pulmonary artery and the RV in response to exercise may have contributed to a reduced 
right ventricular end-diastolic pressure (RVEDP)61, reduced right ventricle hypertrophy58–
60,62,64,125,129, and reduced pulmonary artery thickness63 in the MCT trained models. In 
contrast, exercise training did not modify cardiac output57, or right ventricle systolic pressure 
(RVSP).63,65However, some data have suggested the heart hypertrophy found in MCT trained 
models could be induced by MCT and not by exercise.63 
 
3.2. Cellular and molecular modifications in cardiac remodelling 
 Exercise preconditioning provides protection against RV dysfunction, remodelling, 
muscle wasting, hypertrophy and fibrosis in MCT models of PAH (Figure 3). The exercise-
derived benefits to cardiac microcirculation might be present in MCT models submitted to 
exercise since there is a direct link between angiogenesis, cardiac hypertrophy and cardiac 
function.128 For instance, insufficient cardiac microvascular growth has recently been 
identified as an important underlying mechanism in the transition from compensatory 
hypertrophy to heart failure.106  
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 Few studies have addressed the impact of exercise training on the metabolic 
modifications promoted by PAH in the heart. Brown and co-workers investigated the changes 
in substrate utilization induced by exercise in myocardium in order to evaluate the metabolic 
shift. Data from immunofluorescence staining of RV for glucose transporter (GLUT-1) 
assessment evidenced a higher content of this glucose transporter in untreated MCT rats when 
compared with untreated healthy animals, suggesting a shift toward glycolytic metabolism 
in cardiac muscle. In their study, both high intensity interval trained and continuous exercise 
trained animals showed evidence of  reduced levels of GLUT-1 in the RV (Figure 3) when 
compared with the MCT sedentary animals.130 Consistent with these findings, is the fact that 
in both cardiac and skeletal muscle, mitochondrial substrate utilization from aerobic to 
anaerobic metabolism contributes to diminished exercise tolerance. Therefore, the impact of 
training on indicators of glycolytic versus oxidative metabolism is particularly relevant in 
Figure 3 – Mechanisms underlying the impact of exercise training in MCT/hypoxia models. Figure made 
using Servier Medical Art.by Servier (https://smart.servier.com/) and modified by the author under the Creative 
Commons Attribution 3.0 Unported License (CCBY 3.0). Abbreviations: ATP: Adenosine Triphosphate; BNP: 
Brain Natriuretic Peptide; ET-1: Endothelin 1; GSK; Glycogen Synthase Kinase; IRS: Insulin Receptor Substrate; 
MHC: Myosin Heavy Chain; PI3K: Phosphoinositide 3-kinase; SERCA-2a: Sarco(endo)plasmatic reticulum 
calcium ATPase; TNF-α: Tumor necrosis factor α; TWEAK: TNF-related weak inducer of apoptosis. Figure was 
made using Servier Medical Art. 
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PAH, since this pathology has been associated with an inefficient metabolic shift, as 
previously mentioned in this review.131,132  
Exercise training modulates the glycogen synthase kinase (GSK) signalling pathway 
(Figure 3) in the RV. In exercise trained MCT rats, a decrease in the ratio between the 
phosphorylated (inactive protein with pro-hypertrophic properties) and dephosphorylated 
(active protein with anti-hypertrophic properties) forms of the protein GSK-3β is observed. 
GSK-3β is implicated in cardiac growth and regulates the calcineurin/nuclear factor of 
activated T cells (NFAT) signalling pathway through phosphorylation of NFAT, opposing 
the role of the phosphatase calcineurin. NFAT phosphorylation prevents its translocation to 
the nucleus where it activates the transcription of hypertrophic response genes.128 
The inflammatory response in the RV of MCT models (Figure 3) is also changed. 
Animals submitted to four weeks of moderate-intensity exercise training showed a reduction 
in the expression of tumour necrosis factor-related weak inducer of apoptosis (TWEAK) 
receptors, compared to the control group.82 TWEAK is a member of the TNF receptor 
superfamily, a cell surface-associated transmembrane protein linked to the stimulation of cell 
growth, induction of inflammatory cytokines and stimulation of apoptosis.128,133 This 
cytokine acts on the RV through the activation of NF-κB signalling.89 However, exercise 
prevented the PAH-related overexpression of p100/p52 and Rel B subunits from this 
pathway, and diminished the expression of TWEAK receptors in the heart of an MCT rat 
model.58 The anti-inflammatory effect of exercise training was also related with increased 
NO bioavailability130, and induced a shift of MMPs activity from MMP-9 to MMP-2 activity 
promoting a decrease in deposition of collagen in the heart.128   
The effect of moderate-intensity exercise training prior to and following the 
development of PAH on the MHC isoform profile of the RV has also been evaluated in two 
preclinical models (Figure 3). Exercise was shown to significantly prevent increases in total 
MHC content and β/α MHC ratio in sedentary PAH animals.58,62 The PAH-related increase 
in β/α MHC ratio lead to reduced activity of the myosin ATPase enzyme, and consequently 
to slowing of myocyte contraction.62 The switch from alpha to beta-MHC is widely used as 
an indicator of maladaptive cardiac remodelling. These benefits of exercise training in RV 
remodelling were also associated with increased SERCA2a content.58,62 
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Modifications in the ubiquitin/proteasome system are crucial for cardiac remodelling 
in response to pathological stresses. For instance, the upregulation of muscle RING-finger 
protein-1 (MuRF1), atrogin-1 and TRAF6 E3 ligases have been shown to promote cardiac 
dysfunction.128 The E3 ligase atrogin-1 is also elevated in the RV of rats with PAH.58 The 
transcription of atrogin-1 can be directly induced by FoxO3 through the IG-1/PI3K/Akt 
signalling axis and its inhibition has been related with prevention of pathological cardiac 
remodelling.134,135 Concerning the effect of exercise training, four weeks of moderate-
intensity treadmill running prior to PAH induction prevented the increase in atrogin-1 
expression in the heart of animals with PAH.58   
Finally, exercise training promotes an improvement in the aerobic capacity of the heart, 
which is directly associated with the cellular adaptations, namely mitochondrial biogenesis, 
improved efficiency of OXPHOS, reduction in the transition pore permeability of 
mitochondria and increased antioxidant activity.136  Moreover, as previously mentioned, it is 
well known that apoptosis is an event associated with various features of cardiac pathology. 
The expression of proteins involved in apoptosis in the RV is influenced by aerobic 
exercise.133 For example, five weeks of treadmill aerobic exercise was able to decrease 
caspase 3 expression in MCT-treated rats when compared with sedentary MCT rats. Since 
caspase 3 mediates mitochondrial permeability, its downregulation will lead to a reduction 
in permeability, and thus a reduction in apoptotic signalling mediated by Akt.60 These 
findings suggest exercise plays an antiapoptotic role in this model of PAH.  
 
4. Final remarks 
 Despite major discoveries have been made these past years concerning the 
mechanisms underlying the development of PAH, mortality rates remain high and available 
treatments mainly focus the alterations presents in the lung, excluding the heart as possible 
therapeutic target.1 The awareness of the importance of the RV in PAH has increased 
considerably. Nowadays, there is a clear view of the RV and the pulmonary circulation as a 
functional unit. In this perspective, it is important to understand the cooperation between this 
functional unit. Currently, several studies already have characterized the cellular and 
molecular alterations in the RV of MCT models, allowing the identification of potential new 
therapeutic approaches targeting the heart.52,70,95,137 Exercise training is widely known for its 
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preventive and therapeutic properties in several chronic diseases.138 In patients with PAH, 
exercise training improves exercise tolerance, functional capacity and quality of life.123,126,139 
However, there is still a glaring lack of information regarding the direct effect of exercise 
training in PAH, specifically in the mechanism underlying such changes, and several 
potentially difficult crossroads continue to be the target of studies. Is it better to use exercise 
training as a preventive or therapeutic approach? Which type of exercise produces more 
benefit? What duration is recommended? In this way, a more comprehensive set of 
information could be developed about the effects of exercise training in PAH. 
 From this point of view, the work that we are current developing aims at 
understanding the impact of treadmill exercise training in the modulation of the molecular 
pathways underlying right ventricle dysfunction in pulmonary arterial hypertension, in a 
monocrotaline rat model, specifically focusing on cardiac regeneration (C-Kit, neuregulin-
1), extracellular matrix remodelling (fibrosis, collagen; MMPs/TIMPs activity) and 
metabolism (GLUT-1 expression, glyceraldehyde 3 phosphate dehydrogenase expression, 
citrate synthase activity; ATP synthase expression; PGC-1α). 
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57. Handoko, M. L., de Man, F. S., Happé, C. M., Schalij, I., Musters, R. J. P., Westerhof, N., Postmus, 
P. E., Paulus, W. J., van der Laarse, W. J. & Vonk-Noordegraaf, A. Opposite Effects of Training in 
Rats With Stable and Progressive Pulmonary Hypertension. Circulation 120, 42–49 (2009). 
58. Nogueira-Ferreira, R., Moreira-Gonçalves, D., Silva, A. F., Duarte, J. A., Leite-Moreira, A., Ferreira, 
R. & Henriques-Coelho, T. Exercise preconditioning prevents MCT-induced right ventricle 
remodeling through the regulation of TNF superfamily cytokines. Int. J. Cardiol. 203, 858–866 
(2016). 
59. Enache, I., Favret, F., Doutreleau, S., Goette Di Marco, P., Charles, A.-L., Geny, B. & Charloux, A. 
Downhill exercise training in monocrotaline-injected rats: Effects on echocardiographic and 
haemodynamic variables and survival. Arch. Cardiovasc. Dis. 110, 106–115 (2017). 
36 
 
60. Colombo, R., Siqueira, R., Conzatti, A., Fernandes, T. R. G., Tavares, A. M. V., Araújo, A. S. D. R. 
& Belló-Klein, A. Aerobic Exercise Promotes a Decrease in Right Ventricle Apoptotic Proteins in 
Experimental Cor Pulmonale. J. Cardiovasc. Pharmacol. 66, 246–253 (2015). 
61. Brown, M. B., Chingombe, T. J., Zinn, A. B., Reddy, J. G., Novack, R. A., Cooney, S. A., Fisher, A. 
J., Presson, R. G., Lahm, T. & Petrache, I. Novel assessment of haemodynamic kinetics with acute 
exercise in a rat model of pulmonary arterial hypertension. Exp. Physiol. 100, 742–754 (2015). 
62. Moreira-Gonçalves, D., Ferreira, R., Fonseca, H., Padrão, A. I., Moreno, N., Silva, A. F., Vasques-
Nóvoa, F., Gonçalves, N., Vieira, S., Santos, M., Amado, F., Duarte, J. A., Leite-Moreira, A. F. & 
Henriques-Coelho, T. Cardioprotective effects of early and late aerobic exercise training in 
experimental pulmonary arterial hypertension. Basic Res. Cardiol. 110, 57 (2015). 
63. Colombo, R., Siqueira, R., Becker, C. U., Fernandes, T. G., Pires, K. M., Valença, S. S., Souza-
Rabbo, M. P., Araujo, A. S. & Belló-Klein, A. Effects of exercise on monocrotaline-induced changes 
in right heart function and pulmonary artery remodeling in rats. Can. J. Physiol. Pharmacol. 91, 38–
44 (2013). 
64. Pacagnelli, F. L., de Almeida Sabela, A. K. D., Okoshi, K., Mariano, T. B., Campos, D. H. S., 
Carvalho, R. F., Cicogna, A. C. & Vanderlei, L. C. M. Preventive aerobic training exerts a 
cardioprotective effect on rats treated with monocrotaline. Int. J. Exp. Pathol. 97, 238–247 (2016). 
65. Colombo, R., Siqueira, R., Conzatti, A., de Lima Seolin, B. G., Fernandes, T. R. G., Godoy, A. E. G., 
Litvin, I. E., Silva, J. M. A., Tucci, P. J. F., da Rosa Araújo, A. S. & Belló-Klein, A. Exercise training 
contributes to H2O2/VEGF signaling in the lung of rats with monocrotaline-induced pulmonary 
hypertension. Vascul. Pharmacol. 87, 49–59 (2016). 
66. Voelkel, N. F., Quaife, R. A., Leinwand, L. A., Barst, R. J., McGoon, M. D., Meldrum, D. R., Dupuis, 
J., Long, C. S., Rubin, L. J., Smart, F. W., Suzuki, Y. J., Gladwin, M., Denholm, E. M. & Gail, D. B. 
Right ventricular function and failure: Report of a National Heart, Lung, and Blood Institute working 
group on cellular and molecular mechanisms of right heart failure. Circulation 114, 1883–1891 
(2006). 
67. Archer, S. L., Fang, Y.-H., Ryan, J. J. & Piao, L. Metabolism and Bioenergetics in the Right Ventricle 
and Pulmonary Vasculature in Pulmonary Hypertension. Pulm. Circ. 3, 144–152 (2013). 
68. Voelkel, N. F., Gomez-Arroyo, J., Abbate, A., Bogaard, H. J. & Nicolls, M. R. Pathobiology of 
pulmonary arterial hypertension and right ventricular failure. Eur. Respir. J. 40, 1555–1565 (2012). 
69. Forfia, P. R., Fisher, M. R., Mathai, S. C., Housten-Harris, T., Hemnes, A. R., Borlaug, B. A., 
Chamera, E., Corretti, M. C., Champion, H. C., Abraham, T. P., Girgis, R. E. & Hassoun, P. M. 
Tricuspid Annular Displacement Predicts Survival in Pulmonary Hypertension. Am. J. Respir. Crit. 
Care Med. 174, 1034–1041 (2006). 
70. Naeije, R. & Manes, A. The right ventricle in pulmonary arterial hypertension. Eur. Respir. Rev. 23, 
476–487 (2014). 
71. Price, L. C., Wort, S. J., Perros, F., Dorfmüller, P., Huertas, A., Montani, D., Cohen-Kaminsky, S. & 
Humbert, M. Inflammation in Pulmonary Arterial Hypertension. Chest 141, 210–221 (2012). 
72. Haddad, F., Doyle, R., Murphy, D. J. & Hunt, S. A. Right ventricular function in cardiovascular 
disease, part II: Pathophysiology, clinical importance, and management of right ventricular failure. 
Circulation 117, 1717–1731 (2008). 
73. Sánchez-Trujillo, L., Vázquez-Garza, E., Castillo, E. C., García-Rivas, G. & Torre-Amione, G. Role 
of Adaptive Immunity in the Development and Progression of Heart Failure: New Evidence. Arch. 
Med. Res. 48, 1–11 (2017). 
74. Sydykov, A., Mamazhakypov, A., Petrovic, A., Kosanovic, D., Sarybaev, A. S., Weissmann, N., 
Ghofrani, H. A. & Schermuly, R. T. Inflammatory Mediators Drive Adverse Right Ventricular 
37 
 
Remodeling and Dysfunction and Serve as Potential Biomarkers. Front. Physiol. 9, (2018). 
75. Yoshida, K., Abe, K., Saku, K. & Sunagawa, K. Inhibition of Nuclear Factor-kappaB-Mediated 
Inflammation Reverses Fibrosis and Improves RV Function in Rats with Pulmonary Artery Banding. 
J. Card. Fail. 22, S198 (2016). 
76. Glezeva, N., Horgan, S. & Baugh, J. A. Monocyte and macrophage subsets along the continuum to 
heart failure: Misguided heroes or targetable villains? J. Mol. Cell. Cardiol. 89, 136–145 (2015). 
77. Van Linthout, S. & Tschöpe, C. Inflammation – Cause or Consequence of Heart Failure or Both? 
Curr. Heart Fail. Rep. 14, 251–265 (2017). 
78. Gabriele, P., Zhi Fang, S., Tonny D.T., T., Carsten, K., Hideo A., B., Michael, E., Markus, F., 
Thomas, W., Hans H., S. & Mario C., D. Activation of the cardiac interleukin-6 system in advanced 
heart failure. Eur. J. Heart Fail. 3, 415–421 (2001). 
79. Prins, K. W., Archer, S. L., Pritzker, M., Rose, L., Weir, E. K., Sharma, A. & Thenappan, T. 
Interleukin-6 is independently associated with right ventricular function in pulmonary arterial 
hypertension. J. Hear. Lung Transplant. 37, 376–384 (2018). 
80. Wang, J.-J., Zuo, X.-R., Xu, J., Zhou, J.-Y., Kong, H., Zeng, X.-N., Xie, W.-P. & Cao, Q. Evaluation 
and Treatment of Endoplasmic Reticulum (ER) Stress in Right Ventricular Dysfunction during 
Monocrotaline-Induced Rat Pulmonary Arterial Hypertension. Cardiovasc. Drugs Ther. 30, 587–598 
(2016). 
81. Luitel, H., Sydykov, A., Schymura, Y., Mamazhakypov, A., Janssen, W., Pradhan, K., Wietelmann, 
A., Kosanovic, D., Dahal, B. K., Weissmann, N., Seeger, W., Grimminger, F., Ghofrani, H. A. & 
Schermuly, R. T. Pressure overload leads to an increased accumulation and activity of mast cells in 
the right ventricle. Physiol. Rep. 5, e13146 (2017). 
82. Nogueira-Ferreira, R., Moreira-Gonçalves, D., Silva, A. F., Duarte, J. A., Leite-Moreira, A., Ferreira, 
R. & Henriques-Coelho, T. Exercise preconditioning prevents MCT-induced right ventricle 
remodeling through the regulation of TNF superfamily cytokines. Int. J. Cardiol. 203, 858–866 
(2016). 
83. Nicolls, M. R. & Voelkel, N. F. The Roles of Immunity in the Prevention and Evolution of Pulmonary 
Arterial Hypertension. Am. J. Respir. Crit. Care Med. 195, 1292–1299 (2017). 
84. Judelson, D. A., Maresh, C. M., Yamamoto, L. M., Farrell, M. J., Armstrong, L. E., Kraemer, W. J., 
Volek, J. S., Spiering, B. A., Casa, D. J. & Anderson, J. M. Effect of hydration state on resistance 
exercise-induced endocrine markers of anabolism, catabolism, and metabolism. J. Appl. Physiol. 105, 
816–824 (2008). 
85. Olschewski, A., Berghausen, E. M., Eichstaedt, C. A., Fleischmann, B. K., Grünig, E., Grünig, G., 
Hansmann, G., Harbaum, L., Hennigs, J. K., Jonigk, D., Kuebler, W. M., Kwapiszewska, G., 
Pullamsetti, S. S., Stacher, E., Weissmann, N., Wenzel, D. & Schermuly, R. T. Pathobiology, 
pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 
2018. Int. J. Cardiol. 272, 4–10 (2018). 
86. Brown, R. D., Ambler, S. K., Mitchell, M. D. & Long, C. S. THE CARDIAC FIBROBLAST: 
Therapeutic Target in Myocardial Remodeling and Failure. Annu. Rev. Pharmacol. Toxicol. 45, 657–
687 (2005). 
87. Turner, N. A., Das, A., Warburton, P., O’Regan, D. J., Ball, S. G. & Porter, K. E. Interleukin-1α 
stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. Am. J. Physiol. 
Circ. Physiol. 297, H1117–H1127 (2009). 
88. Turner, N., Mughal, R., Warburton, P., Oregan, D., Balls, S. & Porter, K. Mechanism of TNFα-
induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: Effects of statins and 
thiazolidinediones. Cardiovasc. Res. 76, 81–90 (2007). 
38 
 
89. Sun, X.-Q., Abbate, A. & Bogaard, H.-J. Role of cardiac inflammation in right ventricular failure. 
Cardiovasc. Res. 113, 1441–1452 (2017). 
90. Frangogiannis, N. G. Fibroblasts and the extracellular matrix in right ventricular disease. Cardiovasc. 
Res. 113, 1453–1464 (2017). 
91. Baicu, C. F., Li, J., Zhang, Y., Kasiganesan, H., Cooper, G., Zile, M. R. & Bradshaw, A. D. Time 
course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in 
fibroblast postsynthetic procollagen processing. Am. J. Physiol. Circ. Physiol. 303, H1128–H1134 
(2012). 
92. Okada, M., Harada, T., Kikuzuki, R., Yamawaki, H. & Hara, Y. Effects of Telmisartan on Right 
Ventricular Remodeling Induced by Monocrotaline in Rats. J. Pharmacol. Sci. 111, 193–200 (2009). 
93. Wetzl, V., Tiede, S. L., Faerber, L., Weissmann, N., Schermuly, R. T., Ghofrani, H. A. & Gall, H. 
Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic 
Pulmonary Arterial Hypertension. Lung 195, 489–496 (2017). 
94. Pedram, A., Razandi, M., O’Mahony, F., Lubahn, D. & Levin, E. R. Estrogen Receptor-β Prevents 
Cardiac Fibrosis. Mol. Endocrinol. 24, 2152–2165 (2010). 
95. Nadadur, R. D., Umar, S., Wong, G., Eghbali, M., Iorga, A., Matori, H., Partow-Navid, R. & Eghbali, 
M. Reverse right ventricular structural and extracellular matrix remodeling by estrogen in severe 
pulmonary hypertension. J. Appl. Physiol. 113, 149–158 (2012). 
96. Safdar, Z., Tamez, E., Chan, W., Arya, B., Ge, Y., Deswal, A., Bozkurt, B., Frost, A. & Entman, M. 
Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial 
Hypertension. JACC Hear. Fail. 2, 412–421 (2014). 
97. Benisty, J. I., Folkman, J., Zurakowski, D., Louis, G., Rich, S., Langleben, D. & Moses, M. A. Matrix 
Metalloproteinases in the Urine of Patients With Pulmonary Arterial Hypertension. Chest 128, 572S 
(2005). 
98. Huang, J., Wolk, J. H., Gewitz, M. H. & Mathew, R. Caveolin-1 expression during the progression of 
pulmonary hypertension. Exp. Biol. Med. 237, 956–965 (2012). 
99. Bai, Y., Wang, H., Liu, M., Wang, Y., Lian, G.-C., Zhang, X.-H., Kang, J. & WANG, H.-L. 4-
Chloro-DL-phenylalanine protects against monocrotaline-induced pulmonary vascular remodeling 
and lung inflammation. Int. J. Mol. Med. 33, 373–382 (2014). 
100. Spinale, F. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a 
potential therapeutic target. Cardiovasc. Res. 46, 225–238 (2000). 
101. Sakata, Y., Yamamoto, K., Mano, T., Nishikawa, N., Yoshida, J., Hori, M., Miwa, T. & Masuyama, 
T. Activation of Matrix Metalloproteinases Precedes Left Ventricular Remodeling in Hypertensive 
Heart Failure Rats. Circulation 109, 2143–2149 (2004). 
102. Deschamps, A. & Spinale, F. Pathways of matrix metalloproteinase induction in heart failure: 
Bioactive molecules and transcriptional regulation. Cardiovasc. Res. 69, 666–676 (2006). 
103. Haworth, S. G. The cell and molecular biology of right ventricular dysfunction in pulmonary 
hypertension. Eur. Hear. J. Suppl. 9, H10–H16 (2007). 
104. De Boer, R. A., Pinto, Y. M. & Van Veldhuisen, D. J. The Imbalance Between Oxygen Demand and 
Supply as a Potential Mechanism in the Pathophysiology of Heart Failure: The Role of Microvascular 
Growth and Abnormalities. Microcirculation 10, 113–126 (2003). 
105. Itescu, S., Kocher, A.A. & Schuster, M.D. Heart Fail Rev 8, 253 (2003) 
106. Shiojima, I. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the 
transition to heart failure. J. Clin. Invest. 115, 2108–2118 (2005). 
39 
 
107. Potus, F., Ruffenach, G., Dahou, A., Thebault, C., Breuils-Bonnet, S., Tremblay, È., Nadeau, V., 
Paradis, R., Graydon, C., Wong, R., Johnson, I., Paulin, R., Lajoie, A. C., Perron, J., Charbonneau, E., 
Joubert, P., Pibarot, P., Michelakis, E. D., Provencher, S. & Bonnet, S. Downregulation of 
MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. 
Circulation 132, 932–943 (2015). 
108. Borgdorff, M. A. J., Dickinson, M. G., Berger, R. M. F. & Bartelds, B. Right ventricular failure due to 
chronic pressure load: What have we learned in animal models since the NIH working group 
statement? Heart Fail. Rev. 20, 475–491 (2015). 
109. Wilkins, B. J. & Molkentin, J. D. Calcium–calcineurin signaling in the regulation of cardiac 
hypertrophy. Biochem. Biophys. Res. Commun. 322, 1178–1191 (2004). 
110. Wu, X., Zhang, T., Bossuyt, J., Li, X., McKinsey, T. A., Dedman, J. R., Olson, E. N., Chen, J., 
Brown, J. H. & Bers, D. M. Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte 
excitation-transcription coupling. J. Clin. Invest. 116, 675–682 (2006). 
111. Heineke, J. & Molkentin, J. D. Regulation of cardiac hypertrophy by intracellular signalling 
pathways. Nat. Rev. Mol. Cell Biol. 7, 589–600 (2006). 
112. Brancaccio, M., Hirsch, E., Notte, A., Selvetella, G., Lembo, G. & Tarone, G. Integrin signalling: The 
tug-of-war in heart hypertrophy. Cardiovasc. Res. 70, 422–433 (2006). 
113. Kolwicz, S. C., Purohit, S. & Tian, R. Cardiac metabolism and its interactions with contraction, 
growth, and survival of cardiomyocytes. Circ. Res. 113, 603–616 (2013). 
114. Stanley, W. C., Lopaschuk, G. D., Hall, J. L. & McCormack, J. G. Regulation of myocardial 
carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological 
interventions. Cardiovasc. Res. 33, 243–257 (1997). 
115. Bernardo, B. C., Weeks, K. L., Pretorius, L. & McMullen, J. R. Molecular distinction between 
physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. 
Pharmacol. Ther. 128, 191–227 (2010). 
116. Ryan, J. J., Huston, J., Kutty, S., Hatton, N. D., Bowman, L., Tian, L., Herr, J. E., Johri, A. M. & 
Archer, S. L. Right ventricular adaptation and failure in pulmonary arterial hypertension. Can. J. 
Cardiol. 31, 391–406 (2015). 
117. Piao, L., Sidhu, V. K., Fang, Y. H., Ryan, J. J., Parikh, K. S., Hong, Z., Toth, P. T., Morrow, E., 
Kutty, S., Lopaschuk, G. D. & Archer, S. L. FOXO1-mediated upregulation of pyruvate 
dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in 
pulmonary hypertension: therapeutic benefits of dichloroacetate. J. Mol. Med. (Berl). 91, 333–346 
(2013). 
118. Brittain, E. L., Talati, M., Fessel, J. P., Zhu, H., Penner, N., Calcutt, M. W., West, J. D., Funke, M., 
Lewis, G. D., Gerszten, R. E., Hamid, R., Pugh, M. E., Austin, E. D., Newman, J. H. & Hemnes, A. 
R. Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial 
Hypertension. Circulation 133, 1936–1944 (2016). 
119. Kaur, G., Singh, N., Lingeshwar, P., Siddiqui, H. H. & Hanif, K. Poly (ADP-ribose) polymerase-1: 
An emerging target in right ventricle dysfunction associated with pulmonary hypertension. Pulm. 
Pharmacol. Ther. 30, 66–79 (2015). 
120. Li, Y., Li, Y., Shi, F., Wang, L., Li, L. & Yang, D. Osthole attenuates right ventricular remodeling via 
decreased myocardial apoptosis and inflammation in monocrotaline-induced rats. Eur. J. Pharmacol. 
818, 525–533 (2018). 
121. Zuo, X.-R., Wang, Q., Cao, Q., Yu, Y.-Z., Wang, H., Bi, L.-Q., Xie, W.-P. & Wang, H. Nicorandil 
Prevents Right Ventricular Remodeling by Inhibiting Apoptosis and Lowering Pressure Overload in 
Rats with Pulmonary Arterial Hypertension. PLoS One 7, e44485 (2012). 
40 
 
122. Dorn, G. W. Molecular Mechanisms That Differentiate Apoptosis from Programmed Necrosis. 
Toxicol. Pathol. 41, 227–234 (2013). 
123. Weinstein, A. A., Chin, L. M. K., Keyser, R. E., Kennedy, M., Nathan, S. D., Woolstenhulme, J. G., 
Connors, G. & Chan, L. Effect of aerobic exercise training on fatigue and physical activity in patients 
with pulmonary arterial hypertension. Respir. Med. 107, 778–784 (2013). 
124. Mereles, D., Ehlken, N., Kreuscher, S., Ghofrani, S., Hoeper, M. M., Halank, M., Meyer, F. J., 
Karger, G., Buss, J., Juenger, J., Holzapfel, N., Opitz, C., Winkler, J., Herth, F. F. J., Wilkens, H., 
Katus, H. A., Olschewski, H. & Grünig, E. Exercise and Respiratory Training Improve Exercise 
Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension. Circulation 
114, 1482–1489 (2006). 
125. Souza-Rabbo, M. P., Silva, L. F. F., Auzani, J. A. S., Picoral, M., Khaper, N. & Bell-Klein, A. Effects 
of a chronic exercise training protocol on oxidative stress and right ventricular hypertrophyin 
monocrotaline-treated rats. Clin. Exp. Pharmacol. Physiol. 35, 944–948 (2008). 
126. Buys, R., Avila, A. & Cornelissen, V. A. Exercise training improves physical fitness in patients with 
pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC 
Pulm. Med. 15, 40 (2015). 
127. Grünig, E., Tiede, H., Enyimayew, E. O., Ehlken, N., Seyfarth, H.-J., Bossone, E., D’Andrea, A., 
Naeije, R., Olschewski, H., Ulrich, S., Nagel, C., Halank, M. & Fischer, C. Assessment and 
Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary 
Hypertension. Circulation 128, 2005–2015 (2013). 
128. Nogueira-Ferreira, R., Moreira-Gonçalves, D., Santos, M., Trindade, F., Ferreira, R. & Henriques-
Coelho, T. Mechanisms underlying the impact of exercise training in pulmonary arterial hypertension. 
Respir. Med. 134, 70–78 (2018). 
129. Natali, A. J., Fowler, E. D., Calaghan, S. C. & White, E. Voluntary exercise delays heart failure onset 
in rats with pulmonary artery hypertension. Am. J. Physiol. Circ. Physiol. 309, H421–H424 (2015). 
130. Brown, M. B., Neves, E., Long, G., Graber, J., Gladish, B., Wiseman, A., Owens, M., Fisher, A. J., 
Presson, R. G., Petrache, I., Kline, J. & Lahm, T. High-intensity interval training, but not continuous 
training, reverses right ventricular hypertrophy and dysfunction in a rat model of pulmonary 
hypertension. Am. J. Physiol. Integr. Comp. Physiol. 312, R197–R210 (2017). 
131. Mainguy, V., Maltais, F., Saey, D., Gagnon, P., Martel, S., Simon, M. & Provencher, S. Peripheral 
muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax 65, 113–117 (2010). 
132. Piao, L., Marsboom, G. & Archer, S. L. Mitochondrial metabolic adaptation in right ventricular 
hypertrophy and failure. J. Mol. Med. 88, 1011–1020 (2010). 
133. Moreira-Gonçalves, D., Ferreira-Nogueira, R., Santos, M., Silva, A. F., Ferreira, R., Leite-moreira, A. 
& Duarte, J. A. Exercise for Cardiovascular Disease Prevention and Treatment. 999, (Springer 
Singapore, 2017). 
134. Schips, T. G., Wietelmann, A., Höhn, K., Schimanski, S., Walther, P., Braun, T., Wirth, T. & Maier, 
H. J. FoxO3 induces reversible cardiac atrophy and autophagy in a transgenic mouse model. 
Cardiovasc. Res. 91, 587–597 (2011). 
135. Soares, L. L., Drummond, F. R., Lavorato, V. N., Carneiro-Junior, M. A. & Natali, A. J. Exercise 
training and pulmonary arterial hypertension: A review of the cardiac benefits. Sci. Sports 33, 197–
206 (2018). 
136. Campos, J. C., Gomes, K. M. S. & Ferreira, J. C. B. Impact of exercise training on redox signaling in 
cardiovascular diseases. Food Chem. Toxicol. 62, 107–119 (2013). 
137. Sutendra, G., Dromparis, P., Paulin, R., Zervopoulos, S., Haromy, A., Nagendran, J. & Michelakis, E. 
D. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis 
41 
 
and a transition from a compensated to a decompensated state in pulmonary hypertension. J. Mol. 
Med. 91, 1315–1327 (2013). 
138. Pedersen, B. K. & Saltin, B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 
different chronic diseases. Scand. J. Med. Sci. Sports 25, 1–72 (2015). 
139. Hargett, L. A., Hartman, L. J., Scruggs, A. K., McLendon, J. M., Haven, A. K. & Bauer, N. N. Severe 
Pulmonary Arterial Hypertensive Rats are Tolerant to Mild Exercise. Pulm. Circ. 5, 349–355 (2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
 
 
43 
 
Suplemmentary Table 1 - Animal models, drug dosage, exercise protocol and main physiological effects and molecular modifications 
in heart and lungs 
Study 
Animal strain 
and BW 
Drug dosage Exercise protocols Physiological modifications Molecular modification 
Souza-Rabbo et 
al., 2008125 
Male Wistar rats 
(160-180g) 
Monocrotaline (60 
mg/Kg BW) 
Treadmill running (50 min, 5 
d/wk, 5wk) at 0.6-0.9 km/h 
↓ RVH 
↑ Survival 
↑ Erythrocyte superoxide dismutase and glutathione 
S-transferase activities 
↓ Erythrocyte lipid peroxidation and catalase activity 
↔ Erythrocyte glutathione peroxidase activity 
Handoko et al., 
200957 
Male Wistar rats 
(150-175g) 
Monocrotaline (60 
mg/Kg BW) 
Treadmill running (30 min, 5 
d/wk, 4wk) at 50% VO2 max 
↔ CO 
↑ RV capilarization 
↓ Survival in progressive PAH 
↑ Exercise capacity in stable PAH 
↓ Collagen deposition 
 
Colombo et al., 
201363 
Male Wistar rats 
(139±15g) 
Monocrotaline (60 
mg/Kg BW) 
Treadmill running (60 min, 5 
d/wk, 3wk) at 60% VO2 max 
↓ PA thickness 
↓ RV interstitial volume 
↑ Myocardial capillarity 
↓ EDP 
↓ p-GSK-3β/GSK-3β protein expression in RV 
Colombo et al., 
201560 
Male Wistar rats 
(146±16g) 
Monocrotaline (60 
mg/kg BW) 
Treadmill running (60 min, 5 
d/wk, 3wk) at 60% VO2 max 
↔ AT/ET 
↓ RVH 
 
↓ Hydrogen peroxide concentration in RV 
↑ RV p-Akt 
↓ Caspase 3 protein expression 
↔ RV PI3K, Akt and Bax/Bcl-2 protein expression 
Brown et al., 
201561 
Male Sprague-
Dawley rats 
(300g) 
Monocrotaline (50 
mg/kg BW) 
Treadmill running (45 min at 75% 
reserve VO2) 
↓ RVSP  ↓ eNOS protein expression and activity  
Hargett et al., 
2015139 
Male Sprague-
Dawley rats (160-
200g) 
Sugen 5416 (20 mg/kg 
BW) 
Treadmill running (3 sessions) ↔ Exercise capacity  
Natali et al., 
2015129 
Male Wistar rats 
(200g) 
Monocrotaline 
(60mg/kg BW) 
Voluntary running (3 to 4 weeks) 
↓ RVH 
↑Survival 
↑ myocyte contractility 
↓ cardiac remodelling 
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Moreira-
Gonçalves et al., 
201562 
Male Wistar rats 
(150 g) 
Monocrotaline 
(60mg/kg BW) 
Treadmill running (60 min, 5 
d/wk, 2 or 4wk) at 30 m/min 
↓ RVH 
Restoring RHR 
Restore EDP and TAU 
Restore MAICR 
↑ TAPSE 
↑ Survival 
↓ BNP mRNA expression 
↑ SERCA 2a protein expression 
↑ VEGF mRNA expression 
↑ Mitochondrial complex V activity 
↓Collagen 
↓ β/α MyHC protein expression 
↓ ET-1 mRNA expression 
↓ serum levels of lactate 
↓ mitochondria complex V nitration 
↔ Atrogin-1 
↔ RV ATP synthase subunit β protein expression 
↓ TNF-α/IL-10 
Nogueira-Ferreira 
et al., 201658 
Male Wistar rats 
(150 g) 
Monocrotaline 
(60mg/kg BW) 
Treadmill running (60 min, 5 
d/wk, 4wk) at 25 m/min 
Prevent BW decrease 
↓ RVH 
Restored EDP and TAU 
↓ PA hypertrophy 
↓ β/αMHC 
↓ Inflammation 
↓ Fibrosis 
↔ Atrogin-1 
 
Colombo et al., 
201665 
Male Wistar (315 
± 34g) 
Monocrotaline 
(60mg/kg BW) 
Treadmill running (60 min, 5 
d/wk, 2 or 4 wk) at 60% VO2 max 
↔ RV SF 
↔ RV DF 
↑ FAC 
↑ RV FS 
↑ lung hydrogen peroxide levels 
↑ VEGF 
↑ PTEN 
↑ p-Akt protein expression 
↔ lung lipid peroxidation 
↔ superoxide dismutase 
↔ catalase activity 
↔ glutathione peroxidase activity 
↔ peroxiredoxin 
↔ PI3K 
↔ Akt protein expression 
Pacagnelli et al., 
201664 
Male Wistar (206 
± 16g) 
Monocrotaline 
(60mg/kg BW) 
Treadmill running (60 min, 5 
d/wk, 11 wk) blood lactate < 1 
mmol/L 
Restore PA flow 
↓ RVH 
 
↑ SOD activity 
↓ LPO 
Enache et al., 
201759 
Male Wistar (224 
± 8g) 
 
Downhill (15°) 
Treadmill running (33 min, 5 
d/wk, 4 wk) at 65% VO2 max 
↓ RVH 
↔ Survival 
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Brown et al., 
2017130 
Male Sprague-
Dawley rats 
Monocrotaline (40 
mg/kg) 
Treadmill running (5 d/wk, 6 wk) 
HIIT: 6 min warm up at 50% 
VO2R + 5 min cycles of 
alternating high and low intensity 
intervals as follows: 2 min at 85–
90% VO2R and 3 min at 30% 
VO2R, totaling 30 min 
CExT: 60 min of uninterrupted 
steady state running at 50% VO2R 
 
↓ RV hypertrophy 
↑ RV function 
HIIT: 
↑ lung eNOS protein expression 
HIIT and CExT: 
↓ RV Glut-1 
↔ RV cytochrome IV protein expression 
 
Zimmer et al., 
201724 
Male Wistar rats 
Monocrotaline (60 
mg/kg) 
Treadmill running (5 d/wk, 60 
min/session during the 1st and 2nd 
week and 50 min/session during 
3rd week) at 60% VO2 max 
 
↑ lung superoxide anion concentration 
↔ lung NO2- concentration 
↔ NOS activity 
↔ eNOS protein expression 
↔ ET-1 receptor type A and B protein expression 
a↑ increase; ↔ maintenance; ↓ decrease 
b AT/ET, acceleration time to ejection time ratio; BNP, brain natriuretic peptide; BW, body weight; CExT, Continuous exercise training; CO, cardiac output; DF, diastolic function; EDP, 
end-diastolic function; eNOS, endothelial nitric oxide synthase; ET-1, Endothelin 1; FAC, fractional area change; FS, fractional shortening; GSK, Glycogen synthase kinase; HIIT, High-
intensity interval training; IL-10, interleukin 10; LPO, lipid peroxidation; MHC, myosin heavy chain; MAICR, myocardial acceleration in isovolumetric contraction and relaxation; NO2-, 
nitrogen dioxide; NOS, nitric oxide synthase; PA, pulmonary artery; PAH, pulmonary arterial hypertension; RHR, resting heart rate; RV, right ventricle; RVH, right ventricle hypertrophy; 
RVFS, right ventricle fractional shortening; RVSP, right ventricle systolic pressure; SERCA2a, Sarco(endo)plasmatic reticulum calcium ATPase; SOD, superoxide dismutase; SP, systolic 
pressure; SF, systolic function; TAPSE, Tricuspid annular plane systolic excursion; TAU, time constant of isovolumetric relaxation; TNF-α, tumour necrosis factor alpha; PVR, peripheral 
vascular resistance; VEGF, vascular endothelial growth factor. 
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CHAPTER III  
Therapeutic effect of exercise training in the metabolic remodelling 
of right ventricle in an experimental animal model of pulmonary 
arterial hypertension 
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1. Introduction 
 Pulmonary arterial hypertension (PAH) is a devastating disease characterized by 
progressive obliteration of the pulmonary vasculature, right heart failure and premature 
death.1 Despite the central role displayed by right ventricular (RV) function in terms of 
patients prognosis,2,3 little is known about the pathophysiology of RV failure.4,5 It has been 
suggested that metabolic remodelling in the RV plays a central role in the progression to RV 
failure.6 Whereas in the adult healthy heart fatty acid oxidation (FAO) is the predominant 
energy source7,8, the severely hypertrophic RV of PAH patients relies on glucose oxidation 
to support contraction .9,10 Indeed, the shift in substrate utilization from FAO to glycolysis 
has been shown in both PAH animal models and patients, which was paralleled with RV 
dysfunction.11 The right ventricle undergoes pathological changes in order to guarantee 
homeostasis of the heart-lung axis. In the hypertrophied and failing heart the increased 
systolic wall stress in the ventricular wall will lead to an increase in the energy demand, 
whereas the increased size of the cardiomyocytes and the decreased capillary density is 
anticipated to diminish the ratio oxygen supply/demand, thus contributing to insufficient 
oxygen delivery to the RV and promoting ischemia.12 Thus, the RV is obligated to switch to 
a more efficient source of ATP, glycolysis.13 Glycolysis is a common response to ischemia, 
which when sufficiently severe, impairs energetics and reduces RV function, creating a 
vicious cycle.14 The lower formation of ATP due to the switch from FAO to glycolysis 
results in a lower energy supply which may originate functional impairment to the 
overloaded heart.15 For the heart to work efficiently, ATPases like sarco/endoplasmatic 
reticulum Ca2+ ATPase (SERCA) and myosin ATPase require a high free energy of ATP 
hydrolysis. Those mechanisms are guaranteed by cytosolic creatine kinase (CK) which 
reversibly catalyses the transfer of high-energy phosphate from phosphocreatine (PCr) to 
adenosine diphosphate (ADP) producing ATP and creatine (Cr).16 In PAH, a reduction in 
expression of CK, low levels of ATP and PCr are associated with worse outcomes.17  
 Exercise training promotes a wide range of health benefits such as improving the 
function and health of cardiovascular tissues, as well as the greater tolerance of the heart to 
injury.18 In the setting of PAH, exercise training is now considered to be safe in stable 
patients and it was shown to effectively improve  exercise tolerance, pulmonary arterial 
pressure and quality of life.19 Moreover, pre-clinical data supports that the benefits provided 
by exercise training could be due to its effects on the modulation of several PAH-related 
changes at the level of the RV, lungs and skeletal muscle.20,21 Specifically regarding the RV, 
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our group showed that exercise preconditioning prevented cardiac hypertrophy and RV 
diastolic dysfunction. At a molecular level, exercise modulated the TWEAK/NF-κB 
signalling axis and prevented the shift in MHC isoforms towards an increased expression of 
beta-MHC. Exercise preconditioning also prevented the increase of atrogin-1 expression, 
and induced a shift of MMP activity from MMP-9 to MMP-2 activity.22 In addition, we also 
showed that early and late aerobic exercise training were capable to improve cardiac function 
despite persistent right pressure-overload, and to increase exercise tolerance and survival, 
with greater benefits when exercise was started earlier in the course of PAH. This was 
accompanied by improvements in the markers of cardiac remodelling (SERCA2a), 
neurohumoral activation (lower endothelin-1, brain natriuretic peptide and preserved 
vascular endothelial growth factor mRNA), and mitochondrial oxidative capacity.23  
 Despite this knowledge, little is known about the impact of exercise on RV metabolic 
changes occurring in the setting of PAH. During exercise, the heart has a greater energy 
demand, which translates into a greater continuous generation of ATP in order to sustain the 
contractile function.13 Most of the ATP used by cardiomyocyte is originated in the oxidative 
phosphorylation (OXPHOS) system, harboured in mitochondria. This system is manly 
fuelled by fatty acid oxidation, also located at this organelle. Therefore, it is not surprising 
that the density of mitochondria in cardiomyocytes is highly correlated with the workload of 
the heart.15 However, the metabolic adaptations promoted by exercise training in the RV of 
PAH subjects is poorly comprehended. 
 In order to add new insights on the impact of exercise training on PAH-induced 
cardiac remodelling, we explored the therapeutic effect of two weeks of treadmill exercise 
in the metabolic adaptation of RV using an animal model of chemically induced PAH. 
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2. Material and Methods 
2.1. Animals 
 Male Wistar rats with 4 weeks of age were obtained from Charles River Laboratories 
(Barcelona). After arrival, animals were housed in groups of five rats per cage, in a 
controlled environment at a room temperature of 22ºC, with inverted 12:12 hours light-dark 
cycle, in order to match animals handling and training with their most active period and have 
free access to food and water. The experimental protocol was performed according to the 
Portuguese law on animal welfare and conform to the Guide for the Care and Use of 
Laboratory Animals published by US National Institute of Health (NIH Publication No. 85-
23, Revised 2011). 
 Animals were divided into sedentary injected with monocrotaline (MCT) or vehicle 
(MCT+SED, n=25 and V+SED, n=10, respectively) and 2-weeks exercise training 2 weeks 
after being injected with MCT (MCT+EX, n=15). The number of animals per group was 
determined based on the expected mortality and on the analysis (hemodynamic, histology 
and biochemistry) predicted. MCT animals received a subcutaneous injection of 
monocrotaline (MCT; 60 mg/kg, Sigma, Barcelona, Spain) or equal volume of vehicle 
(1mL/kg of NaCl 0.9%) at 8-weeks of age. Regarding the exercise training protocol, after 1 
week of habituation, animals were exercised for 60 min/session with a running speed of 25 
m/min, no grade, 5 days/week. The habituation period consisted of a first interaction of the 
animal with the treadmill in which a controlled increase of time and intensity was applied 
until the values of the defined protocol were reached. At day 28-29 after MCT or vehicle 
administration, animals were prepared for hemodynamic evaluation with pressure-volume 
catheters. At the end of the experiments, samples from right ventricle were collected and 
stored accordingly biochemical analysis. Figure 1 summarizes the experimental protocol 
that was followed.  
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Figure 1. Overview of the experimental protocol followed in this study. After arrival, animals spent one 
week in habituation protocol to the treadmill, after which they were randomly divided into three experimental 
groups: healthy sedentary (V+SED, n=10), sedentary injected with monocrotaline (MCT+SED, n=25) and two 
weeks of exercise training two weeks after monocrotaline injection (MCT+EX, n=15). Animals from 
MCT+EX group started the exercise-training programme with 8 weeks of age. It consisted of treadmill running 
60 min/day, 25 m/min, 5 days/week for 2 weeks. Twenty-eight days after monocrotaline injection 
hemodynamic evaluation was performed and samples were collected. 
 
2.2. Hemodynamic evaluation 
 Twenty-four hours after ending their respective protocols, rats were anaesthetised by 
inhalation with a mixture of 4% sevoflurane with oxygen, intubated for mechanical 
ventilation (respiratory frequency 100 min-1 and weight adjusted tidal volume; Harvard 
Small Animal Ventilator Model 683) and placed over a heating pad (37ºC). The right jugular 
vein was cannulated for fluid administration (prewarned 0.9% NaCl solution) to compensate 
for perioperative fluid losses. A median sternotomy was performed to expose the heart and 
the pericardium was widely opened. One 1.9 F microtip pressure-volume conductance 
catheters (FTS-1912B-8018, Scisense) was inserted by apical puncture on the RV cavity, 
along the ventricular long axis. The catheter was connected to MVP-300 conductance system 
through interface cable (PCU-2000 MPVS, FC-MR-4, Scisense), coupled to PowerLab 
16/30 converter (AD Instruments) and personal computer for data acquisitions. After 
complete instrumentation, the animal preparation was allowed to stabilize for 15 min. 
Hemodynamic recordings were made with respiration suspended at the end of expiration 
under steady-state conditions or during preload reductions (inferior vena cava occlusion). 
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Parameters from conductance catheter were recorded at a sampling rate of 1000 Hz, in order 
to accurately capture all the features of the pressure-volume waveforms produced by the 
fast-beating rat hearts. Data were stored and analysed with Millar conductance data 
acquisition and analysis software (PVAN3.5). 
 
2.3. Biochemical analysis of cardiac muscle 
2.3.1. Cardiac muscle preparation 
 Portions of RV cardiac muscle of approximately 50 mg were homogenised in 1 mL 
of 100 mM phosphate buffer (50 mM KH2PO4, 50 mM Na2HPO4.H20 pH 7.4, 0.1% Triton-
X100, with 200 mM PMSF (1:1000) and phosphatase inhibitor cocktail (P0044 and P5726, 
Sigma 1:1000)). The protein content of the cardiac muscle homogenates was assayed with 
RC-DC™ Protein Assay (Bio-Rad, CA, USA), following the manufacturer’s instructions 
and using BSA as standard. Absorbance was measured at 750 nm in a Multiskan GO 
microplate spectrophotometer (Thermo Scientific, MA, USA). 
2.3.2. Citrate synthase, ATP synthase and lactate dehydrogenase 
activities  
 Citrate synthase (CS) activity was measured according to Coore et al. 25. In brief, the 
CoASH released from the reaction of acetyl-CoA with oxaloacetate was measured by its 
reaction with 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) at 412 nm (molar extinction 
coefficient of 13.6 mM-1cm-1) in a Multiskan GO microplate spectrophotometer (Thermo 
Scientific). 
 ATP synthase activity was using a commercia kit (ab109714). The ATP synthase 
enzyme is immunocaptured within the wells of the microplate and the enzyme is measured 
by monitoring the decrease in absorbance at 340 nm. The conversion of ATP to ADP by 
ATP synthase is coupled to the oxidation reaction of NADH to NAD+ by ATP synthase is 
coupled to the oxidation reaction of NADH to NAD+ with a reduction in absorbance at 340 
nm. 
 Serum levels of lactate were measured using a commercial kit (Randox) used 
according to the manufacturer’s instructions. 
2.3.3. Acylcarnitine and amino acid quantitation 
 Acylcarnitine (AC) and amino acid (AA) quantification was performed using the 
mass spectrometry (MS)-based methodology described by Petucci et al.26 In brief, 100 µL 
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of cardiac muscle homogenate of each sample were added to 360 µL of methanol, followed 
by vortexing and centrifugation at 14000 rpm (10ºC, 5 minutes). Afterwards, 140 µL of 
supernatant were collected to a 96-well plate and 100 µL of methanol containing deuterated 
acylcarnitine internal standard solutions (Cambridge Isotope labs, MA, USA) was added to 
each well. The mixture was subsequently dried using nitrogen at 45ºC and shortly thereafter 
derivatised to the corresponding methyl esters by incubation with 95 µL of 3N methanolic 
HCl at 50ºC for 15 minutes. The samples were then dried once again using nitrogen at 45ºC 
and reconstituted with 200 µL of 80% methanol for flow injection MS/MS in an API 4000 
QTRAP (Sciex, Washington, D.C., USA). 
2.3.4. Immunoblotting analysis 
 Equivalent amounts of protein of each RV homogenate were electrophoresed in 
12.5% SDS-PAGE gels as described by Laemmli.27 Gels were blotted onto a nitrocellulose 
membrane (Amersham™ Protan™, GE Healthcare Lifesciences) in transfer buffer (25 mM 
Tris, 192 mM glycine, 20% methanol) for 2 hours at 200 mA. Non-specific binding was 
blocked for 1 hour in 5% (w/v) non-fat dry milk prepared in TBS-T (100 mM Tris, 1.5 mM 
NaCl, 0.5% Tween 20). Then, membranes were incubated with primary antibody [diluted 
1:1000 in 5% (w/v) non-fat dry milk in TBS-T; mouse monoclonal anti-ATP synthase 
subunit β, ab14730, Abcam; rabbit polyclonal anti-GAPDH, ab9485, Abcam; mouse 
polyclonal anti- GLUT4, ab48547, Abcam; rabbit polyclonal anti-PGC-1α, ab191838, 
Abcam; rabbit  polyclonal anti-ETFDH, ab91508, Abcam; rabbit polyclonal anti-PPARα, 
ab24509, Abcam; mouse ab9485 anti-PPARγ, ab41928, Abcam; Total OXPHOS Rodent 
WB antibody cocktail, ab110413] for 1h at room temperature or overnight at 4ºC. Thereafter, 
membranes were washed and incubated with secondary HRP-conjugated anti-mouse or anti-
rabbit (GE Healthcare Life Sciences; diluted 1:1000 in 5% (w/v) non-fat dry milk in TBS-
T) for 2 hours at room temperature. Immunoreactive bands were detected by enhanced 
chemiluminescence (WesternBright™ ECL, Advansta) according to the manufacturer's 
procedure. Images were recorded using a ChemiDoc™ Imaging System (Bio-Rad) and 
analysed with Image Lab (version 5.0, Bio-Rad). The optical densities obtained were 
expressed in arbitrary units. Protein loading was confirmed by Ponceau S staining. 
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2.4. Statistical analysis 
 Values are presented as mean ± standard deviation for all variables. The 
Kolmogorov-Smirnov test was performed to check the normality of the data. Statistical 
analysis was performed using a one-way analysis of variance (ANOVA) followed by the 
Tukey multiple comparisons post hoc test (parametric data). Results were considered 
significantly different when p < 0.05. GraphPad Prism (version 7.0) was the software used. 
3. Results 
3.1. Effect of MCT-induced PAH and exercise training on 
morphometric and morphological parameters 
 Significant body weight loss was observed in MCT+SED rats (p < 0.05 vs. V+SED) 
(Table 1). Exercise training did not counteract this decrease since no differences where 
noticed between the exercised and sedentary monocrotaline groups. Reduction of body 
weight was related to the loss of skeletal muscle mass once a significant decrease of 
gastrocnemius mass was observed in trained and sedentary MCT-treated rats (p<0.05 
MCT+SED vs V+SED; p<0.01 MCT+EX vs. V+SED) (Table 1). Regarding heart mass, no 
significant differences were found among the different groups. However, when heart mass 
was adjusted to body weight, a significant 13% increase of this ratio was found between 
MCT+SED with V+SED groups (p < 0.05), suggestive of cardiac hypertrophy. Exercise 
training attenuated the increase of heart mass-to-body weight, though without reaching 
statistical significance (p=0.6). No differences between groups were noticed for RV mass 
and RV mass-to-body weight. The lung mass was significantly increased in MCT groups, 
either sedentary or exercised ones (p< 0.01 vs. V+SED) (Table 1). These differences were 
also observed when lung mass was adjusted to body weight, tibia length and right atrium.  
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Table 1.  Effect of MCT and exercise training on morphometric characteristics. 
 Experimental groups 
 V+SED MCT+SED MCT+EX 
Body Weight (g) 349±10 294±30* 284±20** 
Heart (g) 0.858±0.050 0.944±0.090 0.851±0.080 
Right Ventricle (g) 0.181±0.010 0.242±0.050 0.206±0.070 
Right Atrium (g) 0.029±0.010 0.051±0.050 0.034±0.010 
Lungs (g) 1.348±0.080 2.175±0.180** 2.037±0.460** 
Gastrocnemius mass (g) 2.182±0.180 1.842±0.190* 1.713±0.170** 
Heart/Body Weight (g/g) 2.458±0.120 3.271±0.690* 3.009±0.340 
Right Ventricle/Body Weight (g/g) 0.518±0.040 0.851±0.300 0.734±0.280 
Right Atrium/Body Weight (g/g) 0.082±0.015 0.095±0.027 0.119±0.025* 
Lung/Body Weight (g/g) 3.866±0.250 7.532±1.330** 7.158±1.410** 
Gastrocnemius/Body Weight (g/g) 0.0063±0.0004 0.0063±0.0002 0.0060±0.0003 
Body Weight/ Tibia length (g/cm) 92.92±2.79 76.82±9.76** 72.88±5.98** 
Heart/ Tibia length (g/cm) 0.228±0.012 0.247±0.019 0.218±0.018 
Right Ventricle/Tibia length (g/cm) 0.0482±0.0048 0.0632±0.0130 0.0529±0.0174 
Right Atrium/Tibia length (g/cm) 0.0076±0.0015 0.0076±0.0016 0.0086±0.0019 
Lung/Tibia length (g/cm) 0.359±0.03 0.569±0.05** 0.522±0.11* 
Gastrocnemius/Tibia length (g/cm) 0.580±0.04 0.482±0.05* 0.439±0.04*** 
Values are expressed as mean ± standard derivation (*p < 0.05 vs. V+SED; **p < 0.01 vs. V+SED; ***p < 
0.001 vs. V+SED). 
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3.2. Effect of MCT-induced PAH and exercise training on cardiac 
hemodynamics 
 Results from RV hemodynamic evaluation are shown in Table 2. Heart rate was 
significantly reduced in both MCT-treated groups (p<0.05 vs. V+SED). Right ventricular 
overload was increased in both MCT-treated groups, as suggested by the higher maximum 
pressure and end-systolic pressure (p<0.05 vs. V+SED). Pulmonary arterial elastance, a 
marker of pulmonary vascular resistance, was also increased in both groups but significantly 
only in MCT-SED (p<0.05 vs. V+SED).  Regarding parameters of systolic function, we 
found that cardiac output and stroke volume were preserved, while dP/dtmax and maximal 
power were increased in MCT-treated groups. On its turn, diastolic function was 
significantly compromised in MCT+SED, as suggested by their increased end-diastolic 
volume (suggestive of dilation), end-diastolic pressure and tau (p<0.05 vs. V+SED). Of note, 
exercise training was capable to prevent diastolic dysfunction. 
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Table 2. Hemodynamic evaluation of systolic and diastolic function. 
 Experimental groups 
 V+SED MCT+SED MCT+EX 
Heart Rate (bpm) 416.4±14.2 353.3±34.4* 348.0±55.6* 
Arterial Elastance (Ea) (mmHg/µL) 0.2077±0.0225 0.3812±0.1115* 0.2768±0.1120 
Stroke Volume (µL) 113.5±5.8 125.0±32.4 189.9±88.0 
End-systolic Volume (µL) 224.8±25.0 330.2±67.6* 212.2±76.2§§ 
Minimum Volume (µL) 201.8±22.1 313.7±58.3** 197.0±68.2§§ 
dP/dt max (mmHg/sec) 1795±175 2461±505* 2841±387*** 
End-systolic Pressure (mmHg) 23.5±2.3 44.9±10.4** 46.7±11.9** 
Maximum Pressure (mmHg) 24.9±1.9 45.3±10.4** 47.3±11.8** 
Cardiac Output (µL/min) 47220±2133 44868±14391 65292±24905 
Maximal Power (mWatts) 0.73±0.17 1.00±0.35 1.38±0.53* 
End-diastolic Volume (µL) 307.6±24.4 432.3±63.3* 349.1±108.8 
Maximum Volume (µL) 315.5±21.5 438.8±62.4* 353.7±108.9 
dPdt min (mmHg/sec) -1332±111 -2196±520** -2301±409** 
Minimum Pressure (mmHg) 0.70±0.50 2.83±1.98* 0.21±0.03§§ 
End-diastolic Pressure (mmHg) 3.8±1.1 6.1±1.9* 3.2±0.8§§ 
Tau_w (msec) 11.1±1.4 15.1±1.5* 11.1±3.6§ 
Preload adjusted maximal power 
(mWatts/µL2) 12.3±4.4 16.4±6.1 16.9±7.1 
Values are expressed as mean ± standard deviation (*p < 0.05 vs. V+SED; **p < 0.01 vs. SED; ***p < 0.001 
vs. V+SED § p < 0.05 vs MCT+SED; §§ p < 0.01 vs MCT+SED) 
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3.3. Effect of MCT-induced PAH and exercise training on cardiac 
metabolism 
 To unravel the RV metabolic adaptations of cardiac muscle in MCT-induced PAH, 
specific molecular players from the glycolytic and oxidative pathways were assessed. As 
depicted in Figure 2, MCT+SED showed a reduction of glucose transporter 4 (GLUT4; p < 
0.05 vs. V+SED) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; p < 0.05 vs. 
V+SED) content in RV as well as of the electron transferring-flavoprotein-dehydrogenase 
(ETFDH; p < 0.0001 vs. V+SED) that is involved in the transference of electrons resultant 
from fatty acid oxidation to the electron transporter chain,28 and also of ATP synthase β (p 
< 0.001 vs. V+SED). However, no differences of ATP synthase activity were noticed 
(Figure 2, L). Regarding the ratio GAPDH-to-ATP synthase β, a rough marker of the 
metabolic status, no significant changes were detected between groups; however, the ratio 
ETFDH-to-ATP synthase β was significantly reduced in MCT rats (p<0.0001 vs. V+SED), 
suggesting a decreased reliance on fatty acid oxidation for energetic purposes. A significant 
increase of LDH activity was noticed in RV of MCT-treated rats (p<0.01 vs. V+SED).  
Exercise training counteracted the MCT-induced decrease of GLUT4 (p<0.01 vs. 
MCT+SED). The levels of GAPDH, ETFDH and ATP synthase β, and the ratios GAPDH-
to-ATP synthase β and ETFDH-to-ATP synthase β were not modulated by exercise training 
in MCT rats; however, the activity of LDH was also increased in trained MCT rats compared 
to the sedentary ones (p<0.05 vs. MCT+SED; Figure 2, M).  
To better explore the effect of exercise training on MCT-induced OXPHOS 
adaptations, the content of subunits from each OXPHOS complex was assessed. A trend 
similar to the one observed for the other metabolic proteins was noticed. Indeed, exercise 
training did not revert the MCT-induced diminishing of subunits from complex I (p < 0.001 
vs. V+SED), II (p < 0.01 vs. V+SED), III (p < 0.0001 vs. V+SED) and V (p < 0.0001 vs. 
V+SED). A lower ability to produce ATP was noticed in the RV of trained MCT rats (p<0.05 
vs. MCT+SED; Figure 2, L). These metabolic adaptations did not seem to be associated 
with changes in mitochondrial density since no differences of citrate synthase activity were 
observed (Figure 2, K).   
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Figure 2. Effects of MCT-induced PAH and exercise training on right ventricle metabolism. A, GLUT4; 
B, GAPDH; C, ETFDH; D, ATP synthase β; E, GAPDH/ATP synthase β ratio; F, ETFDH/ATP synthase β; G, 
complex I, CI-NDUFB8; H, complex II, CII-SDHB; I, complex III, CIII-UQCRC2; J, complex V, CV-ATP5A 
K, Citrate synthase activity; L, ATP synthase activity; M, Lactate dehydrogenase activity. Representative blots 
are shown above the corresponding graphic – samples were loaded in the gel one per group side-by-side. 
Values are expressed as mean ± standard deviation of n=4-6 (*p < 0.05 vs. V+SED; ** p < 0.01 vs. V+SED; 
***p < 0.001 vs. V+SED; ****p < 0.0001 vs. V+SED; §p < 0.05 vs. MCT+SED; §§ p < 0.01 vs MCT+SED). 
Despite no apparent alterations in the mitochondrial density of RV between groups, 
a significant decrease of the content of the transcription factor involved in the regulation of 
mitochondrial biogenesis, peroxisome proliferator-activated receptor γ coactivator-1 α 
(PGC-1α),29 was observed in MCT+SED rats (p < 0.05 vs. V+SED; Figure 3 A). Exercise 
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training reverted this decrease (p < 0.05 vs. MCT+SED) to values in the range of the ones 
observed in V+SED group. Moreover, the content of the transcription factors involved in the 
regulation of cardiac metabolism, PPAR-α and PPAR-γ, was also significantly decreased in 
MCT+SED group (p < 0.05 and p<0.01 vs. V+SED, respectively). Exercise training only 
reverted MCT-induced decrease of PPAR-γ (p < 0.05 vs. MCT+SED) (Figure 3B and 3C).  
Figure 3. Effects of MCT-induced PAH and exercise training on the metabolic regulation of RV. A, 
PGC1-α; B, PPAR α; C, PPAR γ. Representative blots are shown above the corresponding graphic – samples 
were loaded in the gel one per group side-by-side. Values are expressed as mean ± standard deviation of n=4-
6 (*p < 0.05 vs. V+SED; ** p < 0.01 vs. V+SED; §p < 0.05 vs. MCT+SED). 
 To better comprehend the effect of MCT-induced PAH and exercise training on the 
remodelling of cardiac metabolism, metabolite profiling was performed by MRM MS/MS. 
Regarding the acylcarnitine profile, a significant decrease of β-oxidation intermediates 
concentration was observed in both MCT-treated groups (Figure 4). Notably, no changes 
were detected between groups in the content of 3-hydroxybutyrilcarnitine (C4-OH; data not 
shown), a metabolite from ketone bodies metabolism. Exercise training did not revert this 
trend. Indeed, a higher decrease of C16, C14 and C6 metabolites levels were noticed in 
MCT+EX rats. So, data suggest a lower reliance of RV muscle on fatty acid oxidation for 
energy supply and two weeks of exercise training did not revert this trend.    
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Figure 4. Effects of MCT-induced PAH and exercise training on the RV’s acylcarnitine profile. Bellow 
the graphic, the complete sequence of oxidation of an octadecadienoyl fatty acid (C18:2) is shown; in total, 
nine acetyl carnitine molecules are yielded. Values are expressed as mean ± standard deviation of n=4-6 (*p < 
0.05 vs. V+SED; ** p < 0.01 vs. V+SED; ***p < 0.001 vs. V+SED; ****p < 0.0001 vs. V+SED; §p < 0.05 vs. 
MCT+SED ; §§p < 0.01 vs. MCT+SED; §§§p < 0.001 vs. MCT+SED). 
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 The contribution of amino acids metabolism to right ventricle metabolic remodelling 
was also assessed by MRM MS/MS (Figure 5). Data highlight a significant increase of 
leucine/isoleucine, alanine (p < 0.05 vs. V+SED), valine and glutamate (p < 0.01 vs. V+SED) 
concentrations in the RV of MCT+SED rats. The branched amino acids leucine, isoleucine 
and valine may be a source of acetyl-CoA and succinyl-CoA in the heart, supporting the 
tricarboxylic acid cycle after transamination.30 However, the higher levels of these amino 
acids observed in MCT+SED rats does not support their metabolic utilization to fulfil the 
energetic needs of the RV. Exercise training did not revert MCT-induced increase of 
glutamate and valine (p < 0.05 vs. V+SED), though a trend to lower concentrations of these 
amino acids and of leucine/isoleucine was noticed.  
 
 Figure 5. Effect of MCT-induced PAH and exercise training on the RV muscle content of the amino acids 
Leu/Ile, Val, Ala, Glu and Asp. Values are expressed as mean ± standard deviation of n=4-6 (*p < 0.05 vs. 
V+SED; ** p < 0.01 vs. V+SED; §§p < 0.01 vs. MCT+SED) 
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4. Discussion 
 The present study demonstrates that exercise training counteracts cardiac 
dysfunction and modulates the metabolic remodelling secondary to MCT-induced PAH. The 
improved cardiac phenotype promoted by two weeks of treadmill exercise was related to an 
increased uptake of glucose to cardiomyocytes through GLUT4 followed by its oxidation to 
lactate, and increased PGC1α and PPARγ protein expression.  
The MCT animal model of PAH was chosen to study the therapeutic effect of 
exercise training. Although there are some differences described between this animal model 
and human PAH, the MCT animal model reasonably mimics some features of human PAH 
including vascular remodelling, proliferation of smooth muscle cells, endothelial 
dysfunction, upregulation of inflammatory cytokines, and right ventricle failure. 31 Our data 
added new molecular insights on this animal model, mostly at the metabolic level. 
Experimental evidences point to a decreased uptake of glucose in the RV of sedentary MCT-
treated rats, given by the decreased content of GLUT4 transporter. However, a higher 
efficiency on this metabolite oxidation seems to occur, once increased LDH activity was 
observed. No differences of GAPDH content and GAPDH-to-ATP synthase beta ratio were 
noticed; however, protein levels not always reflect the activity of a metabolic pathway due 
to regulatory mechanisms such as posttranslational modifications.13 This increase in the use 
of glycolysis to obtain energy reflects an attempt to compensate the decrease of fatty acid 
oxidation, given by the content of acylcarnitines and ETFDH, the enzyme that transfer the 
reducing equivalents from fatty acid oxidation to the electron transport chain28, and of 
OXPHOS complexes subunits (Figure 2). In the setting of sustained increase in myocardial 
energetic requirements, transcriptional adaptations occur to adjust to metabolic needs.6 The 
human heart responds to chronic stress, such as ischemia as well as pressure and volume 
overload, by switching the preferential substrate to metabolically support cardiac function. 
PAH-induced metabolic remodelling in the RV is characterized by a higher reliance on 
glycolysis, which requires less oxygen consumption for an equivalent amount of ATP 
synthesis.13 Downregulation of PGC-1α and PPARs target metabolic genes is a hallmark of 
heart failure, contributing to insufficient energy production and further progression of the 
pathology.32 The decreased expression of these transcription factors observed in the RV of 
MCT rats (Figure 3), together with the acylcarnitine profile (Figure 4) confirms the lower 
contribution of fatty acid oxidation and OXPHOS for energy suppling. To make it possible 
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for long chain fatty acids to cross the mitochondrial membrane to undergo fatty acid 
oxidation, they must be converted into acylcarnitines. Once in the mitochondrial matrix, 
fatty acids are oxidized with the formation of reducing equivalents that support OXPHOS.33 
Thus, acylcarnitines profile is probably the most appropriate marker of FAO activity.34 On 
the other hand, the MS analysis of the amino acids profile highlights a significant increase 
of amino acids content, particularly of branched amino acids like leucine/isoleucine (not 
distinguished by MS) and valine, in the RV of MCT-treated rats, compared with the V+SED 
ones (Figure 5). Branched chain amino acids are major amino acids taken up by the heart 
and might energetically support this organ when necessary.30 The increase of amino acids 
pool seem to reflect an imbalance between protein degradation and biosynthesis.35 
Histological findings do not support cardiomyocytes proteolysis since evidences of 
cardiomyocytes hypertrophy were previously reported.23 Thus, data suggest a higher uptake 
of amino acids to the RV of MCT-treated rats. Three amino acids are more abundant in 
blood, namely, glycine, alanine and glutamine, which are substrates of Na+-neutral amino 
acid symporters, such as SNAT1. These amino acids, particularly alanine, might result from 
skeletal muscle proteolysis, the largest reservoir of amino acids from mammals.35 The 
decrease of gastrocnemius mass observed in MCT-treated rats (Table 1) is suggestive of 
muscle proteolysis,36 which may feed other organs besides liver where it is usually used to 
support gluconeogenesis.37  
 The benefits of exercise training were morphologically associated to the reduction of 
fibrosis23 and the improved influx of glucose via GLUT 4 transporter and oxidation through 
glycolysis. Insulin signalling has a central role in the regulation of myocardial metabolism 
by stimulating glucose transport into cardiomyocytes. Therefore, data support the effect of 
exercise training in improving insulin sensitivity in RV.38 This data was further supported 
by the increase of PPAR. The upregulation of this transcription factor may also explain the 
decreased cardiac fibrosis observed in trained MCT rats, as previously reported.39. Glucose 
oxidation with lactate formation was increased in the RV of trained MCT rats, assuring a 
higher energetic supply to RV. Despite experimental evidences of increased mitochondrial 
biogenesis, the contribution of OXPHOS to the metabolic remodelling of RV from these 
animals was discrete. Moreover, the content of free amino acids only slightly decreased in 
MCT-trained rats compared to the MCT -sedentary ones, which may reflect a trend to 
increase its oxidation for energetic purposes or its incorporation in muscle proteins, since no 
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alterations of skeletal muscle mass (Table 1) or cardiomyocytes cross-sectional area23 were 
observed. Moreover, the remodelling of ECM did not seem to contribute to the amino acid 
pool of RV, despite increased MMPs activity previously reported.22 Exercise training-
induced upregulation of insulin signaling, through PI3K/Akt signalling, is expected to 
promote amino acids uptake and incorporation in muscle proteins.35 To the best of our 
knowledge, this is the first study characterizing amino acid profile in the set of PAH.  
5. Conclusion 
 In conclusion, our study shows that exercise training performed after disease 
diagnosis, slows the progression of the disease by modulating the energetic substrate of the 
heart. Future studies should explore the metabolic remodelling of RV and the functional 
adaptations promoted by long-term exercise training, envisioning the prescription of tailored 
exercise programs to PAH patients. 
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CHAPTER IV 
Final Remarks 
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 Aiming to add new insights on the therapeutic effect of exercise training in the set of 
PAH, we performed a narrative review of the literature and an experimental study with the 
monocrotaline (MCT) animal model submitted to two weeks of treadmill exercise training 
after disease diagnosis. Data obtained allowed us to conclude that: 
I. The integrative analysis of data from the literature supports the recommendation of 
exercise training for the management of PAH once it promotes the remodelling of 
ECM (decrease of fibrosis and modulation of MMPs/TIMPs), stimulates 
angiogenesis, reduces inflammation (decreased cell infiltration and levels of TNF-α 
and IL-6), neurohormonal activation/decreased BNP and ET-1 expression) and 
oxidative stress; 
II. Experimental findings showed that exercise training improves cardiac tolerance to 
sustained pressure overload promoted by PAH by restoring diastolic function; 
III. The cardioprotective phenotype provided by exercise training was related to the 
modulation of MCT-induced metabolic remodelling as shown by increased glucose 
uptake through GLUT4 and LDH activity. Exercise training did not counteract the 
downregulation of fatty acid oxidation, OXPHOS activity and amino acids uptake; 
IV. The metabolic effect of exercise training in the RV of MCT rats was mediated by the 
transcription factors PPARγ and PGC-1α, despite no apparent association with 
increased mitochondrial density. 
 
 Taking together, data suggest that exercise training slows the progression to RV 
failure by modulating the energetic substrate of the heart towards glucose utilization, further 
supporting the adjunctive role that exercise training may have in the PAH setting.  
 
